Poster Schedule

8:00 AM – 6:00 PM ADT

(001) Association of ticagrelor versus clopidogrel with major adverse cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention across categories of liver disease

Favorite

8:00 AM – 6:00 PM ADT

(002) Use of Bibliometrics and Altmetrics in Research Impact Assessment of the Canadian Network for Observational Drug Effect Studies: Preliminary Observations

Favorite

8:00 AM – 6:00 PM ADT

(003) What are the main expectations of patients with hemophilia regarding treatment?

Favorite

8:00 AM – 6:00 PM ADT

(004) Meta-analysis of the effects of dexmedetomidine on perioperative inflammatory response and hemodynamics in children with congenital heart disease

Favorite

8:00 AM – 6:00 PM ADT

(006) The Global Seroprevalence of Lyme Disease: A Literature Review

Favorite

8:00 AM – 6:00 PM ADT

(007) Efficacy and Safety of Pyrazobicin by Thermal Infusion in Treatment of Bladder Cancer: A Meta analysis

Favorite

8:00 AM – 6:00 PM ADT

(008) Real-world antiretroviral treatment use patterns among people living with HIV in the U.S.

Favorite

8:00 AM – 6:00 PM ADT

(009) Effectiveness of insulin glargine liraglutide injection in the treatment of type 2 diabetes: a systematic review

Favorite

8:00 AM – 6:00 PM ADT

(010) Association between the Use of Glucagon-like Peptide 1 Agonist and the Risk of Psoriasis in Diabetes Patients Compare to Dipeptidyl Peptidase-4 inhibitors in Taiwan

Favorite

8:00 AM – 6:00 PM ADT

(011) Efficacy and safety of Pingxiao capsules in combination with chemotherapy in the treatment of gastric cancer: a systematic review

Favorite

8:00 AM – 6:00 PM ADT

(012) Meta-analysis of the efficacy and safety of ustekinumab in Crohn's disease

Favorite

8:00 AM – 6:00 PM ADT

(013) Potential Risk Factors for Delirium during Inpatient Rehabilitation: A Matched Case-Control Study

Favorite

8:00 AM – 6:00 PM ADT

(014) Meta-analysis of postoperative safety of cantharidith preparation combined with chemotherapy in the treatment of breast cancer

Favorite

8:00 AM – 6:00 PM ADT

(015) Systematic review of traditional Chinese medicine rhubarb administration via nasal jejunal tube in the treatment of severe acute pancreatitis

Favorite

8:00 AM – 6:00 PM ADT

(016) Efficacy and Safety of Kangai Injection Combined with Platinum-based Chemotherapy for the Treatment of Ovarian Cancer: A Systematic Review and Meta‑analysis

Favorite

8:00 AM – 6:00 PM ADT

(017) Effectiveness of Aspirin in The Treatment of Preeclampsia and Related Pregnancy Outcomes: A Meta Analysis

Favorite

8:00 AM – 6:00 PM ADT

(018) Meta-analysis of traditional Chinese medicine for cough

Favorite

8:00 AM – 6:00 PM ADT

(019) A systematic review of the efficacy and safety of dobutamine in the treatment of sepsis

Favorite

8:00 AM – 6:00 PM ADT

(020) Systematic evaluation of the efficacy of Shenqi Fuzheng injection combined with CAF chemotherapy in the treatment of breast cancer and the clinical effect of peripheral blood picture

Favorite

8:00 AM – 6:00 PM ADT

(021) Community Pharmacy Perspectives on Assessing Kidney Function and Medication Dosing for Advanced Chronic Kidney Disease: A Qualitative Study

Favorite

8:00 AM – 6:00 PM ADT

(022) A systematic review of the safety of crow bile oil emulsion injection combined with GP regimen in the treatment of non-small cell lung cancer

Favorite

8:00 AM – 6:00 PM ADT

(023) Systematic evaluation and meta-analysis on the treatment of moderate and severe cancer pain in cancer patients with traditional chinese medicine combined with three-step analgesic method

Favorite

8:00 AM – 6:00 PM ADT

(024) Risk of Pancreatitis with the Use of Glucagon-like peptide 1 (GLP1) agonists: Analyses of the Post-Marketing FDA Adverse Event Reporting System (FAERS) Database

Favorite

8:00 AM – 6:00 PM ADT

(025) Quantitative benefit-risk assessment of vaccination against COVID-19: a systematic literature review

Favorite

8:00 AM – 6:00 PM ADT

(026) Effectiveness of additional risk minimisation measures: Improving response rates and validity in surveys

Favorite

8:00 AM – 6:00 PM ADT

(027) Increased risk of retinal vascular occlusion in patients receiving cataract surgery: causation or biased association?

Favorite

8:00 AM – 6:00 PM ADT

(028) Non-steroidal anti-inflammatory drug use for migraine and arterial thromboembolic risks: A Danish population-based matched cohort study

Favorite

8:00 AM – 6:00 PM ADT

(029) Trajectories of EU Paediatric Investigation Plans for Oncology approved since 2007 and Resulting Paediatric Cancer Indications

Favorite

8:00 AM – 6:00 PM ADT

(030) Utilization and patient characteristics for the originator and biosimilar trastuzumab products in the United States

Favorite

8:00 AM – 6:00 PM ADT

(031) Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

Favorite

8:00 AM – 6:00 PM ADT

(032) Exploitation of data available in open access on the consumption of medication in France: use case on anti-TNF biosimilars market penetration

Favorite

8:00 AM – 6:00 PM ADT

(034) The Prescription Pattern of Biologics for Crohn’s Disease Patients in Taiwan

Favorite

8:00 AM – 6:00 PM ADT

(037) Purchases of Biological Medicines by the Ministry of Health During the Approval of Biosimilars in Brazil

Favorite

8:00 AM – 6:00 PM ADT

(038) Real-world evaluation of the persistence of the most used drug groups in Rheumatoid Arthritis from 2017 to 2021 in the Public Health System, Brazil

Favorite

8:00 AM – 6:00 PM ADT

(039) Dispensation of Biologic and Non-Biologic Medication in the Brazilian Public Health System

Favorite

8:00 AM – 6:00 PM ADT

(040) Persistence Associated With The Use Of Biologicals For The Treatment Of Ankylosing Spondylitis In The Brazilian Public Health System

Favorite

8:00 AM – 6:00 PM ADT

(041) Predictors of effectiveness of biologic Disease-Modifying Antirheumatic Drugs (bDMARD) in the treatment of psoriatic arthritis

Favorite

8:00 AM – 6:00 PM ADT

(042) Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: systematic review and meta-analysis

Favorite

8:00 AM – 6:00 PM ADT

(043) Renal Adverse Events in Patients with Diabetic Macular Edema Receiving Intravitreal Vascular Endothelial Growth Factors Inhibitors

Favorite

8:00 AM – 6:00 PM ADT

(044) The Impact of External Factors on Spontaneous Reporting Practices: A Time Series Analysis of FAERS Data

Favorite

8:00 AM – 6:00 PM ADT

(045) Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine

Favorite

8:00 AM – 6:00 PM ADT

(046) Differences in Time to Onset Between Spontaneous Reports and Cohort Studies: The Case of the COVID-19 Vaccines

Favorite

8:00 AM – 6:00 PM ADT

(047) Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries

Favorite

8:00 AM – 6:00 PM ADT

(048) Effectiveness of 2-dose COVID-19 Vaccination Against SARS-CoV-2 Infection and Severe Outcomes in Cancer Patients

Favorite

8:00 AM – 6:00 PM ADT

(049) The role of comorbidities in the development of AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands

Favorite

8:00 AM – 6:00 PM ADT

(050) The Characteristics of Abnormal Uterine Bleeding Reports Following COVID-19 Vaccination

Favorite

8:00 AM – 6:00 PM ADT

(051) Background rates of cardiovascular events in patients at high risk of severe COVID-19 before and during the COVID-19 pandemic

Favorite

8:00 AM – 6:00 PM ADT

(052) Adverse post-vaccination events reported with anti-COVID-19 vaccines in Burkina Faso: analysis of spontaneous reports

Favorite

8:00 AM – 6:00 PM ADT

(053) COVID 19 vaccine associated thromboembolic events-A VAERS database study

Favorite

8:00 AM – 6:00 PM ADT

(054) COVID-19-related Pharmacovigilance Surveillance Based On A Spontaneous Reporting Database

Favorite

8:00 AM – 6:00 PM ADT

(055) Time-to-onset of glomerular diseases following COVID-19 vaccination: a case series analysis

Favorite

8:00 AM – 6:00 PM ADT

(056) Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya

Favorite

8:00 AM – 6:00 PM ADT

(057) Assessment of COVID-19 vaccine-related adverse events in VigiAccess

Favorite

8:00 AM – 6:00 PM ADT

(058) The challenges and lessons learnt from conducting COVID-19 monitoring studies through VAC4EU: coordination and management perspective

Favorite

8:00 AM – 6:00 PM ADT

(059) Discovering the Risk Factors of the COVID-19 Vaccine-induced Carditis applying the Machine Learning Approach: Based on Real World Data

Favorite

8:00 AM – 6:00 PM ADT

(060) National U.S. Claims-Based Cohort Study of the Safety of Adenoviral Vector COVID-19 Vaccination during Pregnancy

Favorite

8:00 AM – 6:00 PM ADT

(061) Assessment of COVID-19 and Mpox Vaccine Data when Supplementing Administrative Claims with Immunization Information System Data

Favorite

8:00 AM – 6:00 PM ADT

(062) Factors Associated With Influenza and COVID-19 Vaccination in Older Adults

Favorite

8:00 AM – 6:00 PM ADT

(063) Vaccination Use among Pregnant Women 2016-2022: An Analysis Using Healthcare Claims

Favorite

8:00 AM – 6:00 PM ADT

(064) Monitoring Results From a Postapproval Safety Study of Pfizer-BioNTech COVID-19 Vaccine in the United States: Vaccine Utilization and Incidence Rates of Myocarditis/Pericarditis

Favorite

8:00 AM – 6:00 PM ADT

(065) COVID-19 Vaccine Uptake and Reasons for Hesitancy in a Large Rheumatology Practice Network

Favorite

8:00 AM – 6:00 PM ADT

(066) Multi-regional population-based cohort study for the evaluation of the association between herpes zoster and mRNA vaccinations for SARS-CoV-2: The VENUS Study

Favorite

8:00 AM – 6:00 PM ADT

(067) Validation of a Claims-based Algorithm for Myocarditis/Pericarditis using Medical Chart Review

Favorite

8:00 AM – 6:00 PM ADT

(068) Safety & immUnogenicity of COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED): Preliminary Results of 1031 Patients

Favorite

8:00 AM – 6:00 PM ADT

(069) Identification and characterization of patients receiving a 1st booster of COVID-19 vaccines in a US administrative database

Favorite

8:00 AM – 6:00 PM ADT

(070) Medical chart review of selected adverse event of special interest (AESI) to support rapid safety assessment of the Janssen COVID-19 vaccine (JCOVDEN): a validation study using US electronic health records and claims data

Favorite

8:00 AM – 6:00 PM ADT

(071) Use of Janssen Ad26.COV2.S COVID-19 Vaccine (JCOVDEN) and mRNA COVID-19 Vaccines in Four Large US National Insurers

Favorite

8:00 AM – 6:00 PM ADT

(072) Waning vaccine response after primary vaccine series: Results from the COVID19 VaccinE Response in Rheumatology patients (COVER) study

Favorite

8:00 AM – 6:00 PM ADT

(073) Assessment of mortality after mRNA COVID-19 vaccination in Japan: The VENUS Study

Favorite

8:00 AM – 6:00 PM ADT

(074) Safety of COVID-19 Vaccines Among People With Prior History Of SARS-Cov-2 Infection: Results From the COVID-Vaccine-Monitor Cohort Event Monitoring

Favorite

8:00 AM – 6:00 PM ADT

(075) The Adverse Events Following COVID-19 Vaccination – A Two-year Surveillance conducted in a sentinel site in south India

Favorite

8:00 AM – 6:00 PM ADT

(076) Behaviors and associated determinants of COVID-19 vaccine acceptance and advocacy: a nationwide survey of pharmacy professionals using the Theoretical Domains Framework

Favorite

8:00 AM – 6:00 PM ADT

(077) Updated Real-World Safety of the Pfizer-BioNTech COVID-19 Vaccine in Pregnancy: Data from the Organization of Teratology Information Specialists (OTIS) Pregnancy Registry

Favorite

8:00 AM – 6:00 PM ADT

(078) Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data: Methods and Results of the First Study Feasibility Assessment

Favorite

8:00 AM – 6:00 PM ADT

(079) Vaccines effectiveness against hospitalizations ‘for’ and ‘with’ COVID-19, after clinical histories review

Favorite

8:00 AM – 6:00 PM ADT

(080) Implementation of childhood immunization registry – a post-pandemic intervention to Track the immunization gaps created during COVID-19

Favorite

8:00 AM – 6:00 PM ADT

(081) An Analysis Of The Impact Of The COVID-19 Pandemic Outbreak On Incident Patient Diagnoses In Primary Care In England Using An Interrupted Time Series

Favorite

8:00 AM – 6:00 PM ADT

(082) Visualizing Discrepancies Between a Body of Trials and a Real-World Population: An Example from the COVID-19 Pandemic

Favorite

8:00 AM – 6:00 PM ADT

(083) Definitions of Long COVID Among Published Research Studies

Favorite

8:00 AM – 6:00 PM ADT

(084) Real World Effectiveness of Anticoagulation in Hospitalized COVID-19 Patients using High-Resolution EHR Data in the Presence of Time-varying Confounding: Out with the Old, In with the New

Favorite

8:00 AM – 6:00 PM ADT

(085) Inhaled corticosteroid prescription patterns in UK primary care before and during the COVID-19 pandemic in patients with COPD

Favorite

8:00 AM – 6:00 PM ADT

(086) Inaccuracy of Using ICD-10-CM Diagnosis Code U07.1 to Identify Outpatients with COVID-19 in US Claims Data

Favorite

8:00 AM – 6:00 PM ADT

(087) Risk Prediction of Long COVID with Machine Learning in a Real-World Setting

Favorite

8:00 AM – 6:00 PM ADT

(088) Linking real world data to assess risk of post-acute outcomes following COVID-19 infection in England: the ECHOES national surveillance system

Favorite

8:00 AM – 6:00 PM ADT

(089) Clinical characteristics and healthcare resource utilization among patients identified with post-acute sequelae of COVID-19 (long-COVID) in US administrative claims data

Favorite

8:00 AM – 6:00 PM ADT

(090) Validation of severe COVID-19 information recorded in BIFAP

Favorite

8:00 AM – 6:00 PM ADT

(091) Assessing COVID-19’s impact on condition measurement in claims data

Favorite

8:00 AM – 6:00 PM ADT

(092) Ursodeoxycholic acid may be a new protective factor for severe COVID-19 outcomes – evidence from a nationwide Swedish register-based cohort study within the SCIFI-PEARL project

Favorite

8:00 AM – 6:00 PM ADT

(093) Rapid Production of Pharmacoepidemiology Results to Inform Regulatory Decision-making: Lessons Learned from the COVID-19 Pandemic

Favorite

8:00 AM – 6:00 PM ADT

(094) High dose dexamethasone for COVID-19 not common in a large US hospital network

Favorite

8:00 AM – 6:00 PM ADT

(095) Pilot Surveillance of Infant Lower Respiratory Tract Infections and Respiratory Syncytial Virus in the United States During the COVID Pandemic

Favorite

8:00 AM – 6:00 PM ADT

(096) Association of Xuebijing treatment with clinical outcomes in COVID-19 patients: a retrospective cohort study with propensity score matching

Favorite

8:00 AM – 6:00 PM ADT

(097) The Impact of the COVID-19 Pandemic on the Burden of Opioid Toxicity Deaths Across Canada

Favorite

8:00 AM – 6:00 PM ADT

(098) COVID-19 Infection and Medicines in Pregnancy in Canada

Favorite

8:00 AM – 6:00 PM ADT

(099) Association between race and COVID-19 outcomes in the United States (2020-2021)

Favorite

8:00 AM – 6:00 PM ADT

(100) Timing and Duration of Remdesivir Treatment Among Individuals Hospitalized due to COVID-19 in the Capital Region of Denmark

Favorite

8:00 AM – 6:00 PM ADT

(101) The impact of prenatal maternal mental health during the COVID-19 pandemic on birth outcomes: A study within the CONCEPTION cohort

Favorite

8:00 AM – 6:00 PM ADT

(102) Rise of Underscreening of Depression Post COVID-19 in the US

Favorite

8:00 AM – 6:00 PM ADT

(103) Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19 - An analysis from a population-based cohort within the SCIFI-PEARL project

Favorite

8:00 AM – 6:00 PM ADT

(104) Validation of COVID-related ICD-10-CM Symptom Codes in Electronic Health Records

Favorite

8:00 AM – 6:00 PM ADT

(105) Impact of the COVID-19 pandemic on initiation of anti-diabetic drug consumption pattern in Sweden - An interrupted time series study

Favorite

8:00 AM – 6:00 PM ADT

(106) FACTORS ASSOCIATED WITH SELF-MEDICATION DURING THE COVID-19 PANDEMIC IN CHINCHA – PERU: A CROSS-SECTIONAL STUDY

Favorite

8:00 AM – 6:00 PM ADT

(107) Impact of the COVID-19 Pandemic on Use of Medication and Healthcare Services Among Individuals with Intellectual and Developmental Disabilities in Ontario, Canada

Favorite

8:00 AM – 6:00 PM ADT

(108) Impact of COVID-19 Pandemic on Leukotriene Receptor Antagonists Prescribing

Favorite

8:00 AM – 6:00 PM ADT

(109) Long COVID symptoms following primo- vs reinfection: a multinational cohort analysis of primary care records from Catalonia and the UK

Favorite

8:00 AM – 6:00 PM ADT

(110) Antibacterial Drug Use Among Hospitalized Patients with COVID-19 During Successive Epidemic Waves in Hong Kong

Favorite

8:00 AM – 6:00 PM ADT

(111) Utilization of Telemedicine and antibiotic dispensing before and during the COVID-19 pandemic

Favorite

8:00 AM – 6:00 PM ADT

(112) Postpartum depressive symptoms among Danish new mothers and fathers before and during the COVID-19 pandemic

Favorite

8:00 AM – 6:00 PM ADT

(113) Clinical and Economic Characteristics of Patients Diagnosed with Long COVID: Early Findings from Real-World Data

Favorite

8:00 AM – 6:00 PM ADT

(114) Thromboembolism Risk and Management Pattern in Hospitalized COVID-19 Patients: A Single-Center Experience in Ethiopia

Favorite

8:00 AM – 6:00 PM ADT

(115) Racial and Ethnic Differences in Hospitalized and Critical COVID-19 Treatment, January 2021-April 2022

Favorite

8:00 AM – 6:00 PM ADT

(116) Rates of Antidepressant, Antiepileptic and Anxiolytic Prescribing Among People Living with Dementia During the COVID-19 Pandemic: A Multinational Interrupted Time-Series Analysis

Favorite

8:00 AM – 6:00 PM ADT

(117) Disparities in prescriptions medications use by socioeconomic status and geographical location during COVID-19 pandemic

Favorite

8:00 AM – 6:00 PM ADT

(118) Pediatric and Adolescent Medication Use Before and During COVID-19: A Population-Based Cohort Study in Manitoba, Canada

Favorite

8:00 AM – 6:00 PM ADT

(119) Establishing and Characterising Large COVID-19 Cohorts After Mapping the Information System for Research in Primary Care (SIDIAP) in Catalonia to the OMOP Common Data Model

Favorite

8:00 AM – 6:00 PM ADT

(120) Convalescent Plasma Utilization Among Inpatient U.S. Medicare Beneficiaries Ages 65 and Older Diagnosed with COVID-19 During 2020-2021

Favorite

8:00 AM – 6:00 PM ADT

(121) Characterization of Long COVID among U.S. Medicare Beneficiaries using Claims Data

Favorite

8:00 AM – 6:00 PM ADT

(122) Changes in systemic cancer therapy in Australia during the later COVID-19 pandemic (2020 – 2022): a population-based study

Favorite

8:00 AM – 6:00 PM ADT

(123) Risk of Post-Acute Sequelae of COVID (PASC) Among Patients With Type 2 Diabetes Mellitus on Various Anti-Diabetic Drug Classes

Favorite

8:00 AM – 6:00 PM ADT

(124) The Missing Claimants of the Pandemic: Who Went Without Claims in Canada During the First Two Years of the COVID-19 Pandemic and what Does it Mean for Public and Private drug plans?

Favorite

8:00 AM – 6:00 PM ADT

(125) Impact of COVID-19 on Hormonal Contraceptive Dispensing in Kentucky: An Interrupted Time Series Design

Favorite

8:00 AM – 6:00 PM ADT

(126) Pregnancy during a pandemic: pregnancy occurrence and outcomes during the SARS-CoV-2 pandemic

Favorite

8:00 AM – 6:00 PM ADT

(127) Characteristics of Pregnant People Treated With Sotrovimab for COVID-19 from the COVID-19 International Drug Pregnancy Registry (COVID-PR)

Favorite

8:00 AM – 6:00 PM ADT

(128) Identifying fit-for-purpose existing data sources for COVID-19 pre-exposure prophylaxis in pregnancy

Favorite

8:00 AM – 6:00 PM ADT

(129) Characteristics of data collected in MID-NET®

Favorite

8:00 AM – 6:00 PM ADT

(130) Baseline characteristics of patients with chronic kidney disease and type 2 diabetes (CKD-T2D) initiating anti-hyperglycemic medication: differences before and during the outbreak of COVID-19 in US and UK

Favorite

8:00 AM – 6:00 PM ADT

(131) Depression among Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients before and during the COVID-19 Pandemic Era: a US-claims Based Analysis

Favorite

8:00 AM – 6:00 PM ADT

(132) Efficacy and safety of Remdesivir in COVID-19 patients: An overview of meta-Analysis

Favorite

8:00 AM – 6:00 PM ADT

(133) Immunosuppressive therapy and covid-19-related hospitalization in solid organ transplant recipients: a French nationwide cohort study

Favorite

8:00 AM – 6:00 PM ADT

(134) Medication Delivery Incidents Reported in Community Pharmacies in Canada: A pre- and post- pandemic analysis

Favorite

8:00 AM – 6:00 PM ADT

(136) Quality of Adverse Events Reporting in Clinical Trials of COVID-19 Drugs: a systematic review

Favorite

8:00 AM – 6:00 PM ADT

(137) The Impact of the COVID lock-down on transitions from a once-monthly parenteral therapy for osteoporosis in the U.S. Medicare program

Favorite

8:00 AM – 6:00 PM ADT

(138) Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting

Favorite

8:00 AM – 6:00 PM ADT

(139) Background Rates of Pediatric-Onset Type I Diabetes Before and During the COVID-19 Pandemic

Favorite

8:00 AM – 6:00 PM ADT

(140) Systemic Steroids and its Combination with Remdesivir in Hospitalized COVID-19 Patients: A Retrospective Cohort Study

Favorite

8:00 AM – 6:00 PM ADT

(141) Using administrative data to understand substance misuse patterns in understudied populations: A child welfare sample

Favorite

8:00 AM – 6:00 PM ADT

(142) Focus on types of risk minimization measures for carditis, associated with COVID-19 vaccines- FAERS Database Analysis

Favorite

8:00 AM – 6:00 PM ADT

(143) The Impact of COVID-19 on Mental Health of Health Sciences Students in India: A Survey-Based Study

Favorite

8:00 AM – 6:00 PM ADT

(145) Identification of Gastrointestinal Perforations in Patients with Inflammatory Bowel Diseases: Challenges and Opportunities in Administrative Claims Data

Favorite

8:00 AM – 6:00 PM ADT

(146) Considerations in estimating complete prevalence of cancers using Surveillance, Epidemiology, and End Results (SEER) databases using marginal zone lymphoma (MZL) and acute myeloid leukemia (AML) as case examples

Favorite

8:00 AM – 6:00 PM ADT

(147) Trends in severe COPD exacerbations and mortality following the introduction of ultra-long-acting bronchodilators: an interrupted time-series study between 2007 and 2018 in Quebec, Canada

Favorite

8:00 AM – 6:00 PM ADT

(148) Understanding the journey and complications in patients with type 2 diabetes from the US and the UK: an OMOP-based data network analysis

Favorite

8:00 AM – 6:00 PM ADT

(149) Type 2 Diabetes, the Epidemic: Trends in Incidence and Prevalence, 2004-2020

Favorite

8:00 AM – 6:00 PM ADT

(150) To Link or Not to Link: Insights from comparison of CPRD Aurum and CPRD GOLD with linked Hospital Episode Statistics (HES) APC, HES Outpatient, and Cancer Registry data

Favorite

8:00 AM – 6:00 PM ADT

(151) Development and validation of a risk prediction model for estimating the disease progression in patients with NAFLD

Favorite

8:00 AM – 6:00 PM ADT

(152) Clinically Relevant Real-World Predictors of Hospitalization in Patients with Major Depressive Disorder

Favorite

8:00 AM – 6:00 PM ADT

(153) Evaluating uptake of lung cancer screening in the United States (US) from 2017-2021

Favorite

8:00 AM – 6:00 PM ADT

(154) Epidemiology of Wilson Disease in France: a Nationwide Claims-based Study

Favorite

8:00 AM – 6:00 PM ADT

(155) Replicating a US-claims cardiovascular use case in Japanese databases: opportunities and challenges

Favorite

8:00 AM – 6:00 PM ADT

(156) Incidence and prevalence of common cancers in the United Kingdom from 2000-2019: a population-based cohort study

Favorite

8:00 AM – 6:00 PM ADT

(157) Prevalence and characteristics of patients with advanced/metastatic NSCLC with HER2 mutations

Favorite

8:00 AM – 6:00 PM ADT

(158) Medication Treatment for Depression and Reduced Productivity Among Adults with Major Depressive Disorder in the US

Favorite

8:00 AM – 6:00 PM ADT

(159) Use of US Health Insurance Claims Data to Determine Cause of Death

Favorite

8:00 AM – 6:00 PM ADT

(160) Trajectories of Pharmacological Therapies for Treatment-Resistant Depression: A Large Longitudinal Study based on Commercial Claims Data Linked to Electronic Medical Records

Favorite

8:00 AM – 6:00 PM ADT

(161) Cannabis Use Disorder Symptom Profiles among Individuals Reporting Past-year Cannabis Use in the United States

Favorite

8:00 AM – 6:00 PM ADT

(162) Estimation of global age-specific prevalence of essential tremor by literature review of population-based studies

Favorite

8:00 AM – 6:00 PM ADT

(163) Type 2 Diabetes in France and the UK: Assessing Prevalence, Patient Management Practices, and Clinical Outcomes using Two Large Databases

Favorite

8:00 AM – 6:00 PM ADT

(164) The Risk of Cardiovascular Events in Patients with Resistant Hypertension

Favorite

8:00 AM – 6:00 PM ADT

(165) Incidence of adrenal insufficiency in patients with solid malignancies treated with immune checkpoint inhibitors

Favorite

8:00 AM – 6:00 PM ADT

(166) Real-world Treatment Patterns in Recurrent or Advanced Endometrial Cancer Patients on First-line Systemic Therapy in the United States

Favorite

8:00 AM – 6:00 PM ADT

(167) Heart failure burden in patients with incident CKD in the US: a multi-database FOUNTAIN analysis

Favorite

8:00 AM – 6:00 PM ADT

(168) Improving Incident Hypertension Identification Using Real World Data

Favorite

8:00 AM – 6:00 PM ADT

(169) Treatment with antidiabetics in patients with T2D and moderate to severe CKD: a multi-database FOUNTAIN analysis

Favorite

8:00 AM – 6:00 PM ADT

(170) The Clinical Presentation of and Mortality in Stroke Patients Using Glucocorticoids

Favorite

8:00 AM – 6:00 PM ADT

(171) Factors affecting readmission in patients with surgical site infection: A graphical and prediction model-based approach

Favorite

8:00 AM – 6:00 PM ADT

(172) Lifestyle factors and risk of prostate cancer in men with benign prostatic hyperplasia: A cohort study from UK Biobank

Favorite

8:00 AM – 6:00 PM ADT

(173) Treatment-resistant depression and risk of autoimmune diseases: evidence from a nested case-control study

Favorite

8:00 AM – 6:00 PM ADT

(174) Factors associated with diabetic cataract:a population-based nested case-control study in korea

Favorite

8:00 AM – 6:00 PM ADT

(175) Prevalence of Risk Categories of Chronic Kidney Disease with and without Type 2 Diabetes

Favorite

8:00 AM – 6:00 PM ADT

(176) Long-term metabolic effect of common drugs used for chronic disease. A Mexican cohort study

Favorite

8:00 AM – 6:00 PM ADT

(178) Characteristics of Patients with Resistant Hypertension and Non-resistant Hypertension Identified Using Real-world Data

Favorite

8:00 AM – 6:00 PM ADT

(179) Assessment of the Use of Real-World Data to Support a Study in Patients with Advanced Cancer and Cachexia

Favorite

8:00 AM – 6:00 PM ADT

(180) Utilizing Real World Data from a National Database of Living Donor Kidney Transplants to identify Targeted Subgroups for Planned Intervention Trials to prolong graft survival

Favorite

8:00 AM – 6:00 PM ADT

(181) Annual Trends in the Prevalence of HIV-Lipodystrophy and the use of Stavudine and Zidovudine Among Patients with HIV in the United States (US)

Favorite

8:00 AM – 6:00 PM ADT

(182) Dynamic Change in HBsAg in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Analogues in China

Favorite

8:00 AM – 6:00 PM ADT

(183) Assessment of the Disease Pattern and Drug Utilization among the Neuro ICU Patients

Favorite

8:00 AM – 6:00 PM ADT

(184) Using linkage between routinely and prospectively collected data to improve disease definitions

Favorite

8:00 AM – 6:00 PM ADT

(185) Exploring the heterogeneity of results in multi-database studies: an example using the EXACOS-CV programme

Favorite

8:00 AM – 6:00 PM ADT

(186) FOUNTAIN: a modular research platform for Integrated Real-World Evidence Generation

Favorite

8:00 AM – 6:00 PM ADT

(187) Effect of Metformin on the Risk of Depression: A Systematic Review and Meta-Regression of Observational Studies

Favorite

8:00 AM – 6:00 PM ADT

(188) Risk factor of death after the first suicidal behavior in patients with depressive disorder

Favorite

8:00 AM – 6:00 PM ADT

(189) Bariatric surgery and all-cause mortality: a methodological review of studies using a non-surgical comparator

Favorite

8:00 AM – 6:00 PM ADT

(190) Quantitative Bias Analysis Methods for Summary Level Epidemiologic Data: A Systematic Review

Favorite

8:00 AM – 6:00 PM ADT

(191) Using real-world general practitioner data to study the diagnosis and management of dementia: rationale and design

Favorite

8:00 AM – 6:00 PM ADT

(192) Suspected Falsified Pill Involvement in U.S. Poison Centers Abuse Cases 2019-2022

Favorite

8:00 AM – 6:00 PM ADT

(193) Use of a Clustering Algorithm for Treatment Sequences (TAK®) as a Pre-processing Step to Explanatory and Predictive Models

Favorite

8:00 AM – 6:00 PM ADT

(194) Impact of minimum enrollment period requirements on disease prevalence estimates derived from claims data

Favorite

8:00 AM – 6:00 PM ADT

(195) Curation of a research-ready evidence hub: A development framework for robust, fit-for-purpose data

Favorite

8:00 AM – 6:00 PM ADT

(196) Risk of Psychotropic Treatment Change after Cancer Treatment Initiation Among Cancer Survivors with Mental Health Comorbidity

Favorite

8:00 AM – 6:00 PM ADT

(198) Factors associated with Type2 Diabetes Mellitus development based on Korean National Health Insurance Sharing Service data

Favorite

8:00 AM – 6:00 PM ADT

(199) Knowledge, attitudes and practices towards prevention of hepatitis B infection among students of Gulu University, Uganda

Favorite

8:00 AM – 6:00 PM ADT

(200) Assessment of Potential Risk Factors and Biochemical Predictors for the Interstitial Lung Disease in Patients with Rheumatoid Arthritis

Favorite

8:00 AM – 6:00 PM ADT

(201) Initiation of psychotropic medications after hospital discharge in survivors of critical illness, a retrospective cohort study (2012-2019)

Favorite

8:00 AM – 6:00 PM ADT

(202) Mapping of ICD-9 codes to ICD-10 for commonly assessed comorbidities in claims database studies

Favorite

8:00 AM – 6:00 PM ADT

(203) Low-dose aspirin prescriptions and risk of breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up

Favorite

8:00 AM – 6:00 PM ADT

(204) Long-term Clinical Outcomes in Patients with IgA Nephropathy: Retrospective Cohort Study using a US Electronic Medical Database

Favorite

8:00 AM – 6:00 PM ADT

(205) Effects of sodium-glucose cotransporter 2 inhibitors on the risk of atrial fibrillation in older adults with type 2 diabetes

Favorite

8:00 AM – 6:00 PM ADT

(206) Relative effectiveness of direct-acting oral anticoagulants by dose in patients with atrial fibrillation: A network meta-analysis

Favorite

8:00 AM – 6:00 PM ADT

(207) Risk of Suicidal Behavior after Benztropine Initiation

Favorite

8:00 AM – 6:00 PM ADT

(208) Oral Anticoagulants and Risk of Type 2 Diabetes among Adults with Atrial Fibrillation in the United Kingdom

Favorite

8:00 AM – 6:00 PM ADT

(209) Thiazolidinediones and rheumatoid arthritis in patients with type 2 diabetes mellitus: A retrospective cohort study

Favorite

8:00 AM – 6:00 PM ADT

(210) Trends in the use of raloxifene among older adults, 1999 - 2022

Favorite

8:00 AM – 6:00 PM ADT

(211) Pain control associated with opioid and gabapentinoid prescription after elective knee replacement

Favorite

8:00 AM – 6:00 PM ADT

(212) Cardiovascular safety of non-steroidal anti-inflammatory drug use for gout: A Danish nationwide case-crossover study

Favorite

8:00 AM – 6:00 PM ADT

(213) Marijuana Use and the Risk of Incident Venous Thromboembolism in People with HIV

Favorite

8:00 AM – 6:00 PM ADT

(214) Metformin and Risk of Dementia: Real World Evidence

Favorite

8:00 AM – 6:00 PM ADT

(215) Vitamin D Serum Levels, Supplementation and Suicidal Behavior in Veterans

Favorite

8:00 AM – 6:00 PM ADT

(216) The effect of different levothyroxine administration regimens on thyroid hormone levels: a systematic review, meta-analysis, and network meta-analysis

Favorite

8:00 AM – 6:00 PM ADT

(217) A retrospective cohort study to evaluate the impact of chemotherapy dose delays on survival in breast cancer patients in England

Favorite

8:00 AM – 6:00 PM ADT

(218) Prevalence of Comorbidities and Multimorbidity Among Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Observational Study in a Large US Commercially Insured and Medicare Advantage Population

Favorite

8:00 AM – 6:00 PM ADT

(219) Discharging postoperative patients with an opioid prescription may result in greater reliance on opioid itself and increased healthcare expenditure and mortality

Favorite

8:00 AM – 6:00 PM ADT

(220) Survival Benefits of Adjuvant Oral Endocrine Therapy among Female Medicare Beneficiaries with Early-stage Breast Cancer

Favorite

8:00 AM – 6:00 PM ADT

(221) Incidence of Active Tuberculosis According to Latent Tuberculosis Infection Treatment Before Targeted Therapy in Patients with Rheumatoid Arthritis

Favorite

8:00 AM – 6:00 PM ADT

(222) Weight Loss Associated with Semaglutide Treatment in People with HIV

Favorite

8:00 AM – 6:00 PM ADT

(223) Comparing the Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary PCI in Qatar: A Retrospective Cohort Study Using Real-World Data

Favorite

8:00 AM – 6:00 PM ADT

(225) Associations between antihypertensive medication use and kidney cancer incidence using the Korean nationwide insurance database

Favorite

8:00 AM – 6:00 PM ADT

(226) The Influence of Timing of Cholecystectomy on the Incidence of Post-ERCP Pancreatitis: A Systematic Review & Meta-Analysis

Favorite

8:00 AM – 6:00 PM ADT

(227) Systematic review of externally controlled (EC) trials, data used in them, and their role in regulatory decision-making

Favorite

8:00 AM – 6:00 PM ADT

(228) Self-care Practices Intervention among Adults with Uncontrolled Hypertension in Ibadan, Nigeria

Favorite

8:00 AM – 6:00 PM ADT

(229) A Comprehensive Systematic Review and Meta-Analysis of the Efficacy and Safety of Bexagliflozin in Patients with Type 2 Diabetes Mellitus

Favorite

8:00 AM – 6:00 PM ADT

(231) Lessons learned for data harmonisation and integration from secondary use of randomised controlled trial (RCT) and real-world data in the context of a study to evaluate external comparator arm study results versus RCT results

Favorite

8:00 AM – 6:00 PM ADT

(232) Disease relapse, adverse events and all-cause mortality associated with the use of long-acting injectable antipsychotics versus oral antipsychotics in older people with schizophrenia: a self-controlled case series study

Favorite

8:00 AM – 6:00 PM ADT

(233) Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis

Favorite

8:00 AM – 6:00 PM ADT

(234) Protective effects of medications on cardiovascular events in systemic lupus erythematosus in real-life: a systematic new-user cohort study

Favorite

8:00 AM – 6:00 PM ADT

(235) A population-based evaluation of the real-world effectiveness of nirmatrelvir/ritonavir for reducing hospitalization and mortality from COVID-19

Favorite

8:00 AM – 6:00 PM ADT

(236) Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized with COVID-19: A Target Trial Emulation Study

Favorite

8:00 AM – 6:00 PM ADT

(237) Paxlovid and COVID-19 related hospitalization or death in clinically extremely vulnerable patients

Favorite

8:00 AM – 6:00 PM ADT

(238) The Prevalence of Aortic Stenosis and Aortic Valve Replacement in the United States: A Retrospective Descriptive Claims Study

Favorite

8:00 AM – 6:00 PM ADT

(239) Risk of Carpal Tunnel Syndrome among Patients with Osteoarthritis

Favorite

8:00 AM – 6:00 PM ADT

(240) Clinical and Economic Burden Associated with Prolonged Air Leaks Among Patients Undergoing Thoracic Resection: A Retrospective Database Analysis

Favorite

8:00 AM – 6:00 PM ADT

(241) Characteristics and Outcomes of Patients Undergoing Kidney Ablation Via the NEUWAVE Microwave Ablation System from an Innovative Linkage of Device-Generated and Electronic Health Record Data

Favorite

8:00 AM – 6:00 PM ADT

(242) Analysis of SARS-CoV-2 Testing Patterns Post-PAXLOVID TM Prescription Orders and Analysis of Patients with Multiple PAXLOVID Prescription Orders

Favorite

8:00 AM – 6:00 PM ADT

(243) Influence of Cancer Stage at Diagnosis on Lung Cancer Prognosis of Targetable Molecular Patient Subgroups

Favorite

8:00 AM – 6:00 PM ADT

(244) Survey of Infection Control Practices at Ambulatory Surgery Centers (ASCs) and Outpatient Hospitals that Perform Gastrointestinal Endoscopic Procedures in the United States

Favorite

8:00 AM – 6:00 PM ADT

(245) Efficacy of Hippocampal Avoidance Whole Brain Radiation Therapy in Preventing Neurocognitive Dysfunction Induced by Radiation Therapy in Patients with Brain Metastases: A Systematic Review and Meta-Analysis

Favorite

8:00 AM – 6:00 PM ADT

(246) Artificial intelligence in medical devices: an era of advancement? Or Safety concern?

Favorite

8:00 AM – 6:00 PM ADT

(247) Day-to-Day Variability in Sleep Parameters and Sleep Impairment Among Adolescents With Mood Disorders Treated With Antidepressants

Favorite

8:00 AM – 6:00 PM ADT

(248) A safety Review of Clinical Adverse Events Associated with Cardiovascular Medical Devices under Materiovigilance

Favorite

8:00 AM – 6:00 PM ADT

(249) Bariatric Surgery Utilization Trends in the United States: 2012–2021

Favorite

8:00 AM – 6:00 PM ADT

(250) Self-testing to increase HIV testing among men who have sex with men: results from an integrative literature review

Favorite

8:00 AM – 6:00 PM ADT

(251) Adverse events related to medical devices in the Social Security - EsSalud in Peru (2018-2021): a descriptive analysis of a surveillance system

Favorite

8:00 AM – 6:00 PM ADT

(252) Percutaneous Left Atrial Appendage Occlusion and Risk of Stroke, Hospitalized Bleeding and Death in Medicare Beneficiaries with Atrial Fibrillation

Favorite

8:00 AM – 6:00 PM ADT

(253) Using Linked Registry–Electronic Health Records to Examine Amputations following Peripheral Vascular Intervention

Favorite

8:00 AM – 6:00 PM ADT

(254) Reverse Causation Bias: A Simulation Study Comparing First- and Second-Line Treatments With an Overlap of Symptoms Between Treatment Indication and Studied Outcome

Favorite

8:00 AM – 6:00 PM ADT

(255) Evaluating bias from index date selection methods under varying assumptions in external control analyses using real-world comparators

Favorite

8:00 AM – 6:00 PM ADT

(256) Leveraging External Validation Data to Address Misclassification: The Challenge of Transporting Misclassification Probabilities

Favorite

8:00 AM – 6:00 PM ADT

(257) A Framework for Determining Sample Size for External Control Arms

Favorite

8:00 AM – 6:00 PM ADT

(258) Examining the External Comparator Arm Design: A Simulation Study

Favorite

8:00 AM – 6:00 PM ADT

(259) High-dose vs. standard-dose influenza vaccine and cardiopulmonary hospitalization or mortality: emulating the INVESTED trial using insurance claims data

Favorite

8:00 AM – 6:00 PM ADT

(260) Risk of cardiovascular death and hospitalization for heart failure with sacubitril/valsartan vs. enalapril in clinical practice: application of outcome models developed with clinical trial data from PARADIGM-HF

Favorite

8:00 AM – 6:00 PM ADT

(261) Development and Validation of a Claims-based Algorithm for Moderate-to-Severe Atopic Dermatitis

Favorite

8:00 AM – 6:00 PM ADT

(262) How To Use High Dimensional Approach To Assist Non-Active Comparator Selection In The Retrospective Study: A Case Study For WATCHMAN Device

Favorite

8:00 AM – 6:00 PM ADT

(263) Using claims data to identify the exact indication of use for biological drugs approved for Immune-Mediated Inflammatory Diseases: The VALORE project experience

Favorite

8:00 AM – 6:00 PM ADT

(264) How can advanced analytics and innovative data visualizations improve the understanding of cancer healthcare pathways trajectories?

Favorite

8:00 AM – 6:00 PM ADT

(265) Quality of Electronic Health Records: Variability of Missing Data for Social Determinants of Health by Healthcare Systems

Favorite

8:00 AM – 6:00 PM ADT

(266) Development and Validation of a Tool to Assess Perceptions, Perspectives, Practice and Satisfaction in Patients Taking Oral anticoagulants

Favorite

8:00 AM – 6:00 PM ADT

(267) Impact of using limited duration prevalence (LDP) vs. complete prevalence (CP) on racial/ethnic distributions derived from the Surveillance, Epidemiology, and End Results (SEER) database

Favorite

8:00 AM – 6:00 PM ADT

(268) Evaluation of Commonly Used Real World Data Sources Submitted to ASCO Journals: Initial Steps Toward Furthering Transparent Reporting

Favorite

8:00 AM – 6:00 PM ADT

(269) Measuring Inhaled Medication Compliance: A Study Using a Novel Developed Questionnaire

Favorite

8:00 AM – 6:00 PM ADT

(270) Validation of Real-World Case Definitions for COVID-19 Diagnosis and Severe COVID-19 Illness Among Patients Infected with SARS-CoV-2: Translation of Clinical Trial Definitions to Real-World Settings

Favorite

8:00 AM – 6:00 PM ADT

(271) Validation of a disability proxy for multiple sclerosis using digitized health records from the FlywheelMS cohort

Favorite

8:00 AM – 6:00 PM ADT

(272) Development and Validation of Claims-based Algorithms for Conjunctivitis and Keratitis

Favorite

8:00 AM – 6:00 PM ADT

(273) Comparing the performance of nested case-control and case-crossover study designs for assessing adverse outcomes of concomitant drug use: a simulation study

Favorite

8:00 AM – 6:00 PM ADT

(274) Adapting the prevalent new-user study design to evaluate the effects of drug discontinuation: A simulation study

Favorite

8:00 AM – 6:00 PM ADT

(275) Scalable natural language processing of electronic health records to supplement large-scale covariate adjustment in pharmacoepidemiologic studies

Favorite

8:00 AM – 6:00 PM ADT

(276) Addressing bias due to socioeconomic status in the comparative effectiveness of sodium-glucose co-transporter 2 inhibitors vs. sulfonylureas in patients with type 2 diabetes

Favorite

8:00 AM – 6:00 PM ADT

(277) Assessing joint covariate balance in matched observational studies with high-dimensional categorical variables

Favorite

8:00 AM – 6:00 PM ADT

(278) Negative control outcome adjustment to tackle unmeasured confounding: A case study of oral quinolone and tendon rupture

Favorite

8:00 AM – 6:00 PM ADT

(279) Time-varying propensity score matching as a method to balance baseline covariates and calendar time effects in a real-world effectiveness analysis

Favorite

8:00 AM – 6:00 PM ADT

(A01) Disparities in Guideline-Recommended Pharmacotherapy for Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and Sex: A Nationally Representative Cross-Sectional Analysis of Adults in the United States

Favorite

8:00 AM – 6:00 PM ADT

(A02) Ethnic differences in the indirect impacts of the COVID-19 pandemic on hospitalisations for non-COVID conditions in England: An observational cohort study using OpenSAFELY

Favorite

8:00 AM – 6:00 PM ADT

(A03) Ethnicity differences in risk of cardiovascular events in COVID-19: an England-wide population analysis

Favorite

8:00 AM – 6:00 PM ADT

(A04) Representation of patients of minority race and ethnicity in real-world databases and tumor registries of patients with breast cancer

Favorite

8:00 AM – 6:00 PM ADT

(A05) Social Determinants of Health and Disparities in T2DM Severity in the United States

Favorite

8:00 AM – 6:00 PM ADT

(A06) The Impact of Contextual-Level Social Determinants of Health on Heart Failure Readmission and Mortality in Patients Hospitalized for Heart Failure

Favorite

8:00 AM – 6:00 PM ADT

(A07) The Use of Computational Phenotypes Within Electronic Healthcare Data to Identify Transgender People: A Narrative Review

Favorite

8:00 AM – 6:00 PM ADT

(A08) Using Real-World Data to Support Clinical Trial Diversity and Inclusion Strategies: A Case Study of Cancer of the Cervix

Favorite

8:00 AM – 6:00 PM ADT

(A09) Clinical validation studies for SARS-CoV-2 diagnostic tests in a real-world setting

Favorite

8:00 AM – 6:00 PM ADT

(A10) Continuous Glucose Monitoring in Diabetes Patients with Cognitive Impairment

Favorite

8:00 AM – 6:00 PM ADT

(A11) COVID-RED: A randomized trial demonstrating earlier COVID-19 remote detection using wearable technology and artificial intelligence

Favorite

8:00 AM – 6:00 PM ADT

(A13) Robot-assisted Surgery and Racial and Ethnic Disparities in Post-prostatectomy Outcomes among Prostate Cancer Patients

Favorite

8:00 AM – 6:00 PM ADT

(A14) Systematic Review and Meta-analysis of Clinical Outcomes of Bone Grafting/Reconstruction Following Segmental Long Bone Defects Treated by Induced Membrane Technique

Favorite

8:00 AM – 6:00 PM ADT

(A15) Temporal Trends in Using Catheter Ablation as First-Line Therapy in Patients Diagnosed with Paroxysmal Atrial Fibrillation in the United States

Favorite

8:00 AM – 6:00 PM ADT

(A16) Trends in the Cost of Total Knee Arthroplasty — a US Hospital Database Analysis, 2000 – 2021

Favorite

8:00 AM – 6:00 PM ADT

(A17) Antidepressant Utilization Before and After Initiation of Prenatal Care Among Commercially Insured Pregnant Women in the United States

Favorite

8:00 AM – 6:00 PM ADT

(A18) Maternal Exposure of Benzodiazepine Receptor Agonists and Increased Risk of Neurodevelopmental Disorders in Offspring in Taiwan

Favorite

8:00 AM – 6:00 PM ADT

(A19) Maternal Prescribed Opioid Analgesic Use During Pregnancy and Associations with Neurodevelopmental Disorders in Offspring

Favorite

8:00 AM – 6:00 PM ADT

(A20) Social and Demographic Disparities in the Adherence to Antihypertensive Medication During Pregnancy

Favorite

8:00 AM – 6:00 PM ADT

(A21) Topical azole treatments during pregnancy: Are there risks for the pregnant mother and the fetus? A comparative study in the EFEMERIS database

Favorite

8:00 AM – 6:00 PM ADT

(A22) Utilization of antihypertensives before, during, and after pregnancy

Favorite

8:00 AM – 6:00 PM ADT

(A23) Utilization patterns of Antidepressants in pregnant women: An interrupted time series analysis

Favorite

8:00 AM – 6:00 PM ADT

(A24) Validation study of an ASA prophylaxis variable for preeclampsia prevention

Favorite

8:00 AM – 6:00 PM ADT

(A25) An Observational Post Approval Safety Study of Etanercept and Methotrexate in Treatment of Juvenile Idiopathic Arthritis (JIA) using the German Biologics JIA Registry (BIKER)

Favorite

8:00 AM – 6:00 PM ADT

(A26) Antiepileptic Drug Use in Children Beyond Epilepsy: A Population-Based Longitudinal Study

Favorite

8:00 AM – 6:00 PM ADT

(A27) Incidence of COVID-19 disease severity in a cohort of 4.4 million Italian and Spanish children from 6 healthcare databases

Favorite

8:00 AM – 6:00 PM ADT

(A28) Metrics of Antibiotic Use in Neonatal Intensive Care Units

Favorite

8:00 AM – 6:00 PM ADT

(A29) Natural History of RSV Infection in Outpatient Pediatric Patients in the United States

Favorite

8:00 AM – 6:00 PM ADT

(A30) Overview of Global Real World Data Sources for Pediatric Pharmacoepidemiologic Research

Favorite

8:00 AM – 6:00 PM ADT

(A31) Population-Based Incidence of Influenza-Associated Serious Neuropsychiatric Events

Favorite

8:00 AM – 6:00 PM ADT

(A32) Utilization of beta-blockers among the pediatric population in the United States: a study in the FDA’s Sentinel System from 2008 to 2022

Favorite

8:00 AM – 6:00 PM ADT

(A33) A Retrospective Cohort Study Using Administrative Claims to Compare the Incidence of Eosinophilic Granulomatosis with Polyangiitis in Patients with and without Asthma, Stratified by Asthma Severity

Favorite

8:00 AM – 6:00 PM ADT

(A34) Analgesics Utilization in Danish Cystic Fibrosis Patients

Favorite

8:00 AM – 6:00 PM ADT

(A35) Characteristics, Disease Burden, and Preliminary Outcomes of Patients with Myasthenia Gravis in Real-World Treatment Settings Across the United States

Favorite

8:00 AM – 6:00 PM ADT

(A36) Diagnosed Prevalence of Hypophosphatasia in the United States: a Real World Analysis of Electronic Health Records

Favorite

8:00 AM – 6:00 PM ADT

(A38) Epidemiology of rare kidney diseases in the United Kingdom using a large rare renal registry

Favorite

8:00 AM – 6:00 PM ADT

(A39) Federated Hospital Electronic Health Record Networks for Trial Feasibility Assessments in Rare Diseases: A Pilot Study in Neurofibromatosis Type 1

Favorite

8:00 AM – 6:00 PM ADT

(A40) Identifying Generalized Pustular Psoriasis Flares Using Natural Language Processing of Unstructured Clinical Notes and Structured Procedure Codes

Favorite

8:00 AM – 6:00 PM ADT

(A41) Cardiovascular Risk and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors: A Nationwide Comparative Effectiveness Research Study

Favorite

8:00 AM – 6:00 PM ADT

(A42) Case studies of FDA recently approved product applications using real-world evidence - What are the attributes of studies that support effectiveness determinations?

Favorite

8:00 AM – 6:00 PM ADT

(A43) Decreased Venous Thromboembolic Risk of Estradiol Valerate/Dienogest COCs Compared to First-line COCs Containing Ethinyl Estradiol/Levonorgestrel: Pooled Analysis in a Large Real-World User Population

Favorite

8:00 AM – 6:00 PM ADT

(A44) Lessons Learned from the Development of Machine Learning Models to Estimate Validated Measures Using Real-World Data for Four Chronic Conditions

Favorite

8:00 AM – 6:00 PM ADT

(A45) Machine Learning to Predict Successful Treatment of Atrial Fibrillation by Medical Devices Using Digital Data Linked to EHR Data

Favorite

8:00 AM – 6:00 PM ADT

(A46) Progression to ESRD Among White, Black and Hispanic Diabetic Kidney Disease Patients: Real-World Evidence from Multiple Linked Claims Databases

Favorite

8:00 AM – 6:00 PM ADT

(A47) Use and contribution of registries in registry-based randomized clinical trials: a review

Favorite

8:00 AM – 6:00 PM ADT

(A48) Use of Antibiotics in the ‘Watch’ category of the WHO AWaRe classification in Europe: a DARWIN-EU® multinational network cohort study (EUPAS103381)

Favorite

8:00 AM – 6:00 PM ADT

(A49) Carditis risk following covid-19 vaccination with mRNA (BNT162b2) or inactivated (CoronaVac): a self-controlled cases series and a case-control study

Favorite

8:00 AM – 6:00 PM ADT

(A50) Characterization of U.S. Adults Aged 18–64 Years Vaccinated Against Mpox within the Food and Drug Administration Biologics Effectiveness and Safety (BEST) Initiative

Favorite

8:00 AM – 6:00 PM ADT

(A51) Evaluation of the risk of potential adverse events following bivalent COVID-19 vaccines in Veteran patients

Favorite

8:00 AM – 6:00 PM ADT

(A52) Post-marketing surveillance of human papillomavirus (HPV)-related high-grade cervical disease in a cohort of Chinese women who received the 9-valent HPV vaccine

Favorite

8:00 AM – 6:00 PM ADT

(A53) Safety monitoring of COVID-19 vaccines in multiple European countries: initial results from the COVID-19 Vaccine Monitor (CVM)

Favorite

8:00 AM – 6:00 PM ADT

(A54) The effect of sex on the incidence, latency, duration and burden of adverse events following influenza vaccination

Favorite

8:00 AM – 6:00 PM ADT

(A55) The importance of contextualising overall measures of COVID-19 vaccine effectiveness: the COVIDRIVE-AstraZeneca experience

Favorite

8:00 AM – 6:00 PM ADT

(A56) Vaccine patterns among older adults diagnosed with Guillain-Barré Syndrome and matched counterparts with Medicare insurance, 2006-2019

Favorite

8:00 AM – 6:00 PM ADT

(001) Exploratory Analysis of Patient Characteristics and Treatment Duration in Patients using Esketamine for Treatment-Resistant Depression: A Large Longitudinal Study Linking Commercial Claims Data to Electronic Medical Records

Favorite

8:00 AM – 6:00 PM ADT

(002) Assessing The Impact of the Slow-Release Oral Morphine Drug Shortages in Ontario: a Population-Based Time Series Analysis

Favorite

8:00 AM – 6:00 PM ADT

(003) Survival and drug treatment patterns in multiple myeloma patients exposed to an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory imide drugs

Favorite

8:00 AM – 6:00 PM ADT

(004) Association of Medication Safety Announcements with topical calcineurin inhibitor Prescribing: A repeated cross-sectional analysis

Favorite

8:00 AM – 6:00 PM ADT

(005) Low-Value Prescriptions For Injury Hospitalisations: A Cohort Study

Favorite

8:00 AM – 6:00 PM ADT

(006) Spontaneous reporting of urinary dysfunction associated with polypharmacy: a case/non-case study

Favorite

8:00 AM – 6:00 PM ADT

(007) Prescription Ranitidine Use and Population Exposure in Six Canadian Provinces, 1996 to 2019

Favorite

8:00 AM – 6:00 PM ADT

(008) Association between physician characteristics and antiplatelet medication dispensed to community dwelling New Brunswick older adults following hospital discharge for myocardial infarction between 2009 and 2017

Favorite

8:00 AM – 6:00 PM ADT

(009) Extent of the Ranitidine Shortage and its Impact on Acid Suppression Drug Utilization in Canada and the United States: an Interrupted Time Series Analysis

Favorite

8:00 AM – 6:00 PM ADT

(010) Impacts of Tier-3 drug shortages on utilization trends across Canada: A cross-sectional analysis of 3 drug shortages

Favorite

8:00 AM – 6:00 PM ADT

(011) Assessment of Buprenorphine Dispensing in Texas Following the 2016 Federal-Level Buprenorphine Access Expansion Policies

Favorite

8:00 AM – 6:00 PM ADT

(012) Medical Use and Combination Drug Therapy Among US Adult Users Of Central Nervous System Stimulants: A Cross-Sectional Analysis

Favorite

8:00 AM – 6:00 PM ADT

(013) The impact of lidocaine prescribing reduction strategies: a comparison of two national health services in Europe

Favorite

8:00 AM – 6:00 PM ADT

(014) Use of intra-articular corticosteroid injections among osteoarthritis patients in UK general practice

Favorite

8:00 AM – 6:00 PM ADT

(015) Publicly funded access to prescription medicines in Brazil from 1998 to 2019

Favorite

8:00 AM – 6:00 PM ADT

(017) Utilization of Gonadotropin-Releasing Hormone Agonist Products in Adolescents

Favorite

8:00 AM – 6:00 PM ADT

(018) Primary Care Prescribing of Cardiovascular System Medications (England, 2015-2019): Variation and Associations

Favorite

8:00 AM – 6:00 PM ADT

(019) Real World Evidence (RWE) Couture: attributes of well-fitting regulatory grade evidence for efficacy decision making

Favorite

8:00 AM – 6:00 PM ADT

(020) Gender differences in anticancer drugs among patients with Non-Small Cell Lung Cancer in Taiwan

Favorite

8:00 AM – 6:00 PM ADT

(021) Characteristics of Prescription Drug Fills Using Pharmacy-Pharmacy Benefits Manager (PBM) Discount Programs: The "Goodrx" Model

Favorite

8:00 AM – 6:00 PM ADT

(022) Assessment of Narrow therapeutic Index Drugs and Associated Drug Related Problems: A Prospective Cohort Study

Favorite

8:00 AM – 6:00 PM ADT

(023) Validity of the ISMP Medication Safety Self-Assessment® for Long-Term Care tool in Australian nursing homes

Favorite

8:00 AM – 6:00 PM ADT

(024) Alopecia Areata Severity and Real-World Treatment Patterns

Favorite

8:00 AM – 6:00 PM ADT

(025) Monitoring biological treatments for psoriasis in the Brazilian Public Health System: a real-world study

Favorite

8:00 AM – 6:00 PM ADT

(027) Publicly funded prescription drugs dispensed to community dwelling New Brunswick older adults following hospital discharge for myocardial infarction between 2009 and 2017

Favorite

8:00 AM – 6:00 PM ADT

(028) Assessment of High-Risk Medications Utilization and Prescribing Patterns among Special Populations using WHO Prescribing Indicators

Favorite

8:00 AM – 6:00 PM ADT

(029) Early retirement pensioners diagnosed with mental and behavioral disorders caused by psychoactive substances (ICD F11-19 block) in Germany - characterization and utilization of medical rehabilitation

Favorite

8:00 AM – 6:00 PM ADT

(030) Gender differences in pattern of medication use in the population of Tuscany region, Italy, in 2021

Favorite

8:00 AM – 6:00 PM ADT

(032) Drug Utilization Evaluation of Narrow Therapeutic Index Drugs in A Tertiary Care Teaching Hospital

Favorite

8:00 AM – 6:00 PM ADT

(033) Pharmacists’ Perspectives on Facilitators and Barriers to Pharmacist Prescribing for Patients admitted to Hospital within Nova Scotia Health

Favorite

8:00 AM – 6:00 PM ADT

(034) Trends in Anti-Obesity Drugs Utilization, Spending, and Prices in Medicaid Programs: 1999–2021

Favorite

8:00 AM – 6:00 PM ADT

(035) Best practice implementation project on handwritten prescription practices in a public hospital in Uasin Gishu County, Kenya

Favorite

8:00 AM – 6:00 PM ADT

(036) Efficacy of restricted prescribing protocol of sacubitril valsartan in Heart Failure with reduced Ejection Fraction (HFrEF) in a tertiary center in Saudi Arabia

Favorite

8:00 AM – 6:00 PM ADT

(037) Clinical Characteristics of Patients Prescribed with Dapagliflozin in a Tertiary Care Teaching Hospital in India

Favorite

8:00 AM – 6:00 PM ADT

(038) A cross-national comparison between Denmark and the US on age-stratified psychotropic trends among youths: 2010-2020

Favorite

8:00 AM – 6:00 PM ADT

(039) Describing medication changes near end-of-life: Applied example and methodological considerations

Favorite

8:00 AM – 6:00 PM ADT

(040) Trajectories of Sacubitril/Valsartan Adherence Among Medicare Beneficiaries with Heart Failure

Favorite

8:00 AM – 6:00 PM ADT

(041) Factors associated with opioid overdose and dependence: retrospective cohort study with 959,286 patients initiating opioid therapy

Favorite

8:00 AM – 6:00 PM ADT

(042) The Size Paradox: Comprehensive Data and Better Methods Can Yield Significant Results with Smaller Sample Sizes in Real World Data (Size Doesn’t Always Matter)

Favorite

8:00 AM – 6:00 PM ADT

(043) Association of Recreational and Medical Cannabis Legalization with Opioid Prescribing and Mortality: A Generalized Difference-In-Difference Analysis

Favorite

8:00 AM – 6:00 PM ADT

(044) Assigning Defined Daily Doses (DDD) to Anatomical-Therapeutical-Chemical (ATC) codes that were not addressed by the World Health Organization (WHO): the example of antineoplastics and immunomodulating agents

Favorite

8:00 AM – 6:00 PM ADT

(045) The Impact of the 2016 CDC Guidelines on Opioid Prescribing in Chronic Low Back Pain: An Interrupted Times Series Analysis

Favorite

8:00 AM – 6:00 PM ADT

(046) An evaluation of commonly available imputation methods useful for RWE research

Favorite

8:00 AM – 6:00 PM ADT

(047) Complementary and integrative health modalities to prevent utilization of allopathic medications for dysmenorrhea: A prospective interventional study

Favorite

8:00 AM – 6:00 PM ADT

(048) Antidepressant Adherence Trajectories Before Tamoxifen Initiation and Risk of Subsequent Antidepressant Discontinuation Among US Women with Breast Cancer

Favorite

8:00 AM – 6:00 PM ADT

(049) Investigating the ability to adhere to cardiometabolic medication properties: a retrospective cohort study

Favorite

8:00 AM – 6:00 PM ADT

(050) Real-world management and outcomes for newly diagnosed AML patients initiating Venetoclax and hypomethylating agents in US community practice

Favorite

8:00 AM – 6:00 PM ADT

(051) Utilization of antidepressants in patients with chronic kidney disease: A nationwide cohort study

Favorite

8:00 AM – 6:00 PM ADT

(052) Assessment of medication adherence and its factors influencing poor medication adherence among psoriasis patients: a cross-sectional study

Favorite

8:00 AM – 6:00 PM ADT

(053) Blood Pressure Action Sheet and Medication Adherence for Hypertension: A mixed-method study in Yogyakarta, Indonesia

Favorite

8:00 AM – 6:00 PM ADT

(054) Closing the Gap on Inflammatory Bowel Disease Treatments and the Risk of Cancer: an International Collaboration Combining National Registries with Medical Chart Abstraction

Favorite

8:00 AM – 6:00 PM ADT

(055) Defining Key Deprescribing Measures From Electronic Health Data: Learnings From A Multisite Data Harmonization Project

Favorite

8:00 AM – 6:00 PM ADT

(056) Drug Utilization of Biologic Therapy for Inflammatory Bowel Disease Using Data of An Brazilian Healthcare Administrative Database (2008-2021)

Favorite

8:00 AM – 6:00 PM ADT

(057) Trajectories and predictors of prescription opioid tapering: a retrospective cohort study in Australian primary care

Favorite

8:00 AM – 6:00 PM ADT

(058) Dosing of cannabinoids associated with an opioid-sparing effect: A systematic review of longitudinal studies

Favorite

8:00 AM – 6:00 PM ADT

(059) Predictors of nonadherence to antihypertensives among adult initiating cancer treatment

Favorite

8:00 AM – 6:00 PM ADT

(060) The predictors of exposure to three-drug combinations among older adults in emergency department settings in the US

Favorite

8:00 AM – 6:00 PM ADT

(061) Psychiatric Prescription Drug Utilization and Related Overdoses Among Commercially Insured Individuals in the United States, 2020

Favorite

8:00 AM – 6:00 PM ADT

(062) Acne Vulgaris: Disease Severity and Real-World Treatment Patterns

Favorite

8:00 AM – 6:00 PM ADT

(063) The quality, supply chain, and use of uterotonics in the zone of influence in the Northern region of Ghana – a survey from healthcare providers’ perspective

Favorite

8:00 AM – 6:00 PM ADT

(064) Exposure to actionable pharmacogenomic medications in a nationally representative insurance claims database

Favorite

8:00 AM – 6:00 PM ADT

(065) A comprehensive overview of dispensing durations for all drugs applicable in pharmacoepidemiological studies using Danish data

Favorite

8:00 AM – 6:00 PM ADT

(066) Utility of Procedure Codes in Identifying Use of Long-Acting Cabotegravir in Administrative Claims Data

Favorite

8:00 AM – 6:00 PM ADT

(067) Exposure Patterns of Immune Checkpoint Inhibitors Among Older Medicare Beneficiaries with Non-Small Cell Lung Cancer

Favorite

8:00 AM – 6:00 PM ADT

(068) Clinical and Humanistic Impact of Clinical Pharmacist-Initiated Medication Information Services in Psychiatric Patients

Favorite

8:00 AM – 6:00 PM ADT

(069) Conceptual bases for the standardization of calculation approaches for establishing exposure duration of single drug utilization records in multi-database studies

Favorite

8:00 AM – 6:00 PM ADT

(070) Evaluation of critical care clinical pharmacist services and Predictors in identifying the medication related problems in critically ill patients in South India- A hospital based interventional study

Favorite

8:00 AM – 6:00 PM ADT

(071) Determination of Pill-Burden and Its Association with Treatment Burden among Patients with Advanced Stages of Chronic Kidney Disease in Qatar

Favorite

8:00 AM – 6:00 PM ADT

(072) To Analyze the Utilization Pattern of Antidotes in Poisoned Patients in a Tertiary Care Hospital

Favorite

8:00 AM – 6:00 PM ADT

(073) Adherence to statins and LDL-cholesterol control: a population-based study using primary care data

Favorite

8:00 AM – 6:00 PM ADT

(074) Community Pharmacists Knowledge, Attitude, and Practice towards Hypertensive Patient Counseling in the United Arab Emirates

Favorite

8:00 AM – 6:00 PM ADT

(076) Pharmacist knowledge, attitudes, practice and barriers towards providing health screening services in the community pharmacy

Favorite

8:00 AM – 6:00 PM ADT

(077) Antipsychotic-Induced Metabolic Syndrome - A Review

Favorite

8:00 AM – 6:00 PM ADT

(078) A cross-sectional online survey on ivermectin use for prevention and treatment of SARS-CoV-2 infection in a peruvian population

Favorite

8:00 AM – 6:00 PM ADT

(080) Frequency of potential drug-drug interactions among patients with acute clinical conditions visiting ambulatory patient education center of a tertiary care hospital

Favorite

8:00 AM – 6:00 PM ADT

(081) Real-World Survival Effectiveness of Edaravone in Amyotrophic Lateral Sclerosis: A Propensity Score Weighted, Registry-based, Canada-wide Cohort Study

Favorite

8:00 AM – 6:00 PM ADT

(082) The Utilization Pattern of Glucagon-Like Peptide-1 Receptor Agonist, Dipeptidyl Peptidase-4 Inhibitor, and Sodium Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes Mellitus in a Tertiary Care Hospital- A Retrospective Study

Favorite

8:00 AM – 6:00 PM ADT

(083) Trends and Disparities in Access to Oral Childhood Cancer Medicines in High Income and Low and Middle Income Countries, 2015-2020

Favorite

8:00 AM – 6:00 PM ADT

(084) Treatment Initiation, Time-to-Treatment, Treatment Duration and Treatment Discontinuation of Direct-Acting Antivirals for Hepatitis-C in Manitoba

Favorite

8:00 AM – 6:00 PM ADT

(085) Long-term use of prescription opioids and mortality: a population based, propensity-weighted cohort study with 767,299 patients initiating therapy

Favorite

8:00 AM – 6:00 PM ADT

(086) Data Cleaning to Estimate Dosing Frequency of Zoledronic Acid

Favorite

8:00 AM – 6:00 PM ADT

(087) A Systematic Review of Real-World Treatment Discontinuation of Interferon-free Direct-acting Antivirals in Patients with Hepatitis-C virus

Favorite

8:00 AM – 6:00 PM ADT

(088) Assessment of medication adherence among patients with acute clinical conditions in a tertiary care hospital

Favorite

8:00 AM – 6:00 PM ADT

(089) Prescription analysis emphasizing on medication adherence of antibiotics for lower respiratory tract infection

Favorite

8:00 AM – 6:00 PM ADT

(090) Use of Very Low-Dose Vaginal Estrogens Among Postmenopausal Women in the US

Favorite

8:00 AM – 6:00 PM ADT

(091) Association between the use of different classes of blood pressure-lowering drugs and risk of incident dementia: a multi-database cohort study

Favorite

8:00 AM – 6:00 PM ADT

(093) Adherence patterns one year after initiation of Sodium-glucose cotransporter 2 inhibitors: a national cohort study

Favorite

8:00 AM – 6:00 PM ADT

(094) Plans Change: A Competing Risks Analysis of Time to Unplanned Stopping of Long-Term Outpatient Antibiotic Treatment, 2015-2022

Favorite

8:00 AM – 6:00 PM ADT

(095) Phosphodiesterase Type 5 Inhibitors and The risk of Alzheimer’s Disease in Men with Erectile Dysfunction: A cohort study

Favorite

8:00 AM – 6:00 PM ADT

(096) N-Domain vs. C-Domain Angiotensin Converting Enzyme-inhibitors and the risk of Alzheimer's disease: A cohort study

Favorite

8:00 AM – 6:00 PM ADT

(097) Adverse Drug Reactions in an Ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients

Favorite

8:00 AM – 6:00 PM ADT

(098) Efficacy and safety of Mixed MAOB Inhibitors in Treatment of Adults with Parkinson's Disease: A Systematic Review and Meta-analysis

Favorite

8:00 AM – 6:00 PM ADT

(099) Individual contributions of medications with anticholinergic side effects to high anticholinergic burden in older adults

Favorite

8:00 AM – 6:00 PM ADT

(100) Trends in the Use and Costs of Benzodiazepines and Z-drugs in Canada from 2016 to 2022: a National Repeated Cross-Sectional Study

Favorite

8:00 AM – 6:00 PM ADT

(101) Concurrent Use of Central Nervous System-Acting Medications and Risk for Inpatient Psychiatric and Skilled Nursing Facility Admission Among Young-onset Alzheimer’s Patients

Favorite

8:00 AM – 6:00 PM ADT

(102) Trends in prevalence of polypharmacy and hyper-polypharmacy in the UK primary care: a population-based study from 1999 to 2018

Favorite

8:00 AM – 6:00 PM ADT

(103) Medication Regimen Complexity and Family Caregiver Medication Administration Hassle in Home Hospice

Favorite

8:00 AM – 6:00 PM ADT

(104) Association of physician characteristics and their competency on prescribing of non-steroidal anti-inflammatory drugs (NSAIDs) among patients with congestive heart failure (CHF)

Favorite

8:00 AM – 6:00 PM ADT

(105) Describing Adjuvant Chemotherapy Delivery in Older and Younger Women with Early-Stage Breast Cancer Using Longitudinal Cumulative Dose

Favorite

8:00 AM – 6:00 PM ADT

(106) Association between antibiotics use and encephalopathies-related hospitalization among people living with dementia- a self-controlled case series study

Favorite

8:00 AM – 6:00 PM ADT

(107) An investigation of psychoactive polypharmacy and related sex-differences in older adults with dementia

Favorite

8:00 AM – 6:00 PM ADT

(108) Trends in Concurrent Use of Central Nervous System-Active Medications Among Young-onset Dementia Patients

Favorite

8:00 AM – 6:00 PM ADT

(109) Potentially inappropriate prescribing and its association with adverse drug reaction-related hospital admissions

Favorite

8:00 AM – 6:00 PM ADT

(110) Patterns of Antibiotic Prescribing for Urinary Tract Infections and Pneumonia by Provider Specialty in Nursing Home Care

Favorite

8:00 AM – 6:00 PM ADT

(111) Who You Are And Where You Are Influences Antipsychotic Use in People with Dementia Living in Nursing Homes

Favorite

8:00 AM – 6:00 PM ADT

(112) Pilot Project to Deprescribe Sedative-Hypnotic Drugs to Reduce Risk of Falls in Hospital Patients in Nova Scotia, Canada

Favorite

8:00 AM – 6:00 PM ADT

(113) Trends in osteoporosis drug initiation and use among community dwelling older adults

Favorite

8:00 AM – 6:00 PM ADT

(114) Potentially inappropriate medications among elderly patients in Chinese primary healthcare facilities: a nationwide survey, 2017-2019

Favorite

8:00 AM – 6:00 PM ADT

(115) Drug-Drug Interactions and Adverse Drug Reaction Hospital Admissions in the Older Population: A Prospective Cohort Study

Favorite

8:00 AM – 6:00 PM ADT

(116) Is willingness enough? Willingness to deprescribe is not associated with changes in medication-related outcomes after one year

Favorite

8:00 AM – 6:00 PM ADT

(117) Characteristics of seniors undergoing cognitive assessment or with a recent diagnosis of neurocognitive disorders in Quebec Family Medicine Groups in the GPS study

Favorite

8:00 AM – 6:00 PM ADT

(118) Integrating Social Determinants of Health and Claims Data to Predict a Diagnosis of Depression Using the Medicare Current Beneficiary Survey

Favorite

8:00 AM – 6:00 PM ADT

(119) Empowering the Elderly Patients: A Study on Impact of Virtual Patient Education on Medication Adherence

Favorite

8:00 AM – 6:00 PM ADT

(120) Bipolar Disorder Treatment Changes After Nonfatal Suicide Attempt and Association with Subsequent Suicide Attempts: An Analysis of U.S. Veterans

Favorite

8:00 AM – 6:00 PM ADT

(121) Trends in the prescription of anti-dementia treatments in Spain and the UK: a large network population-based cohort study

Favorite

8:00 AM – 6:00 PM ADT

(122) Long term Comparative Safety of ARNi verses ACEi/ARB: A Real-World Data analysis

Favorite

8:00 AM – 6:00 PM ADT

(123) Disparity in guideline-based antidiabetic drugs prescribing for type 2 diabetes patients in primary healthcare facilities across China, 2017-2019

Favorite

8:00 AM – 6:00 PM ADT

(124) Prescribing Trends of SGLT2 Inhibitors Among Patients with Heart Failure in the U.S., 2013-2020

Favorite

8:00 AM – 6:00 PM ADT

(125) Validating birth proxy algorithms in Medicaid administrative claims

Favorite

8:00 AM – 6:00 PM ADT

(126) Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 analogues (GLP-1a) for cardiovascular risk in Australia (2014-2022)

Favorite

8:00 AM – 6:00 PM ADT

(127) Anticoagulant Treatment and Thromboembolic Events Prior to Diagnosis of Renal Cell Carcinoma: Impact on Stage Distribution

Favorite

8:00 AM – 6:00 PM ADT

(128) Real-World Patterns of Opioid Analgesic, Gabapentinoid, and Benzodiazepine Prescriptions in the United States: A Drug Utilization Study (2017-2021)

Favorite

8:00 AM – 6:00 PM ADT

(129) Appropriate washout period for adverse events of special interest (AESI) in vaccine active surveillance utilizing an administrative claims database

Favorite

8:00 AM – 6:00 PM ADT

(130) Association between mortality and warfarin comparing with direct oral anticoagulants: a population-based cohort study

Favorite

8:00 AM – 6:00 PM ADT

(131) Routine Clinical Use of PD-1/PD-L1 Immune Checkpoint Inhibitors and Survival in Patients With Advanced Cancers: A Danish Population-Based Cohort Study

Favorite

8:00 AM – 6:00 PM ADT

(132) Validated Algorithms to Identify Non-fatal Strokes using Uniform Objective Criteria: A Pooled Clinical Trial Data Analysis

Favorite

8:00 AM – 6:00 PM ADT

(133) Sensitivity Analyses to Assess Robustness of Estimates from Propensity Score Weighting in the Presence of Extremely Large Weights

Favorite

8:00 AM – 6:00 PM ADT

(134) Predictors of Opioid Use Before and After Orthopaedic Surgery in an Australian Setting: A Multicentre, Cross-Sectional, Observational Study

Favorite

8:00 AM – 6:00 PM ADT

(135) Use Of Baclofen For The Treatment Of Alcohol Use Disorders Between 2014 And 2021 In France

Favorite

8:00 AM – 6:00 PM ADT

(136) Secular Trends and Determinants of Hepatitis C Virus Testing during Pregnancy

Favorite

8:00 AM – 6:00 PM ADT

(137) Trends in the Utilisation of Antiepileptic Drugs Following Ischaemic Stroke

Favorite

8:00 AM – 6:00 PM ADT

(138) Evaluating the Application of a Claims-Based Frailty Algorithm in Younger Adults in the US

Favorite

8:00 AM – 6:00 PM ADT

(141) Comorbidity clusters before and after adjuvant endocrine therapy in oldest-old women with breast cancer: An unsupervised machine learning approach

Favorite

8:00 AM – 6:00 PM ADT

(142) Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Dementia in People with Type 2 Diabetes (T2D): A Population-Based Cohort Study

Favorite

8:00 AM – 6:00 PM ADT

(143) Polypharmacy's association to mortality: A methodological case study

Favorite

8:00 AM – 6:00 PM ADT

(144) Hip fracture incidence and post-fracture mortality in Victoria, Australia from 2012 to 2018

Favorite

8:00 AM – 6:00 PM ADT

(145) The European Drug-Drug Interaction (EuroDDI) study protocol: a cross country comparison of the prevalence of drug-drug interactions in the older community-dwelling population

Favorite

8:00 AM – 6:00 PM ADT

(146) The association of gabapentin initiation and neurocognitive changes in non-demented older adults with cognitive symptoms

Favorite

8:00 AM – 6:00 PM ADT

(147) Liraglutide and Risk of Dementia: Real World Evidence

Favorite

8:00 AM – 6:00 PM ADT

(148) Health Care Utilization and Medical Costs in New Users of Once-weekly GLP-1 RAs Compared with New Users of DPP-4is Among Individuals with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Favorite

8:00 AM – 6:00 PM ADT

(149) Effect of Dipeptidyl Peptidase-4 Inhibitors on Fracture Risk in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials

Favorite

8:00 AM – 6:00 PM ADT

(150) Comparative Effectiveness of Pegcetacoplan (PEG) Versus Ravulizumab (RAV) and Eculizumab (ECU) in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Matching-Adjusted Indirect Comparison

Favorite

8:00 AM – 6:00 PM ADT

(151) PRO Reporting and Methodological Rigor in NSCLC RCTs, a Cause for Concern

Favorite

8:00 AM – 6:00 PM ADT

(152) Budget impact of risperidone for adults with Autistic Spectrum Disorder in Brazil: a comparative analysis study between epidemiological demand and real-world data

Favorite

8:00 AM – 6:00 PM ADT

(153) The Bendroflumethiazide versus Indapamide Study for hypertensiON (BISON) cohort study

Favorite

8:00 AM – 6:00 PM ADT

(154) Outpatient Cost of Care among Patients with Colorectal Cancer (CRC) Treated in the Real-World US Community Oncology Setting

Favorite

8:00 AM – 6:00 PM ADT

(155) Cost-Effectiveness of Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma in Canada

Favorite

8:00 AM – 6:00 PM ADT

(156) Anatomical Characterization of Long Bone Femur and Tibial Fractures and Associated Two-Year Risks of Non-Union – A US Database Analysis

Favorite

8:00 AM – 6:00 PM ADT

(157) Unveiling the impact of Digital Health Interventions in Coronary Heart Disease: A Systematic review and Meta-analysis

Favorite

8:00 AM – 6:00 PM ADT

(158) Real-world Outpatient Cost of Care among Patients with Ovarian Cancer (OC) Treated in the US Community Oncology Setting

Favorite

8:00 AM – 6:00 PM ADT

(159) The Effect of Allopurinol and Febuxostat on Blood Pressure in Adults with Chronic Hyperuricemia

Favorite

8:00 AM – 6:00 PM ADT

(160) Trends of Myocarditis/Pericarditis following SARS-CoV-2 Infection: A Real-World Analysis of a Large US Commercial Claims Database Enriched with Ambulatory EMR Data

Favorite

8:00 AM – 6:00 PM ADT

(161) Real-world Outpatient Cost of Care among Patients with Breast Cancer Treated in the US Community Oncology Setting

Favorite

8:00 AM – 6:00 PM ADT

(162) Economic Burden of Gallbladder Cancer in Northeast India: A Hospital-based Prospective Observational Cost-analysis Study

Favorite

8:00 AM – 6:00 PM ADT

(163) Quality of Life of Patients with Mild Cognitive Impairment or Alzheimer's Disease and Their Caregivers in the United States

Favorite

8:00 AM – 6:00 PM ADT

(164) Real-world studies evaluating patients with HER2-low breast cancer: A systematic review and meta-analysis

Favorite

8:00 AM – 6:00 PM ADT

(165) Comparative Efficacy of Pharmacological Interventions for Heart Failure with Reduced Ejection Fraction between Asian and White Patients: A Meta-Analysis of Randomized Outcomes Trials

Favorite

8:00 AM – 6:00 PM ADT

(166) Clinical Outcomes and Treatment Pattern of Older Patients with Heart Failure Across Different Frailty Severity Status: a Nationwide Cohort Study of 38,843 Newly Hospitalized Heart Failure Patients

Favorite

8:00 AM – 6:00 PM ADT

(167) Lorlatinib in the first-line treatment of ALK-positive metastatic/advanced non-small-cell lung cancer: a budget impact analysis

Favorite

8:00 AM – 6:00 PM ADT

(168) Analgesia Versus No-Analgesia in the Management of Neonates Undergoing Mechanical Ventilation in the Intensive Care Setting in Qatar. A Cost-Effectiveness Analysis

Favorite

8:00 AM – 6:00 PM ADT

(169) Association Between Trajectory of Metabolic Syndrome and Knee Pain over 11 Years in Middle-aged Adults: Evidence from Childhood Determinants of Adult Health (CDAH) Study

Favorite

8:00 AM – 6:00 PM ADT

(170) Comparative Efficacy of Pharmacological Therapies for Heart Failure with Reduced Ejection Fraction: A Network Meta-Analysis of Randomized Controlled Trials

Favorite

8:00 AM – 6:00 PM ADT

(171) Treatments and Healthcare Costs Associated with Long Bone Fracture Non-Union - A US Claims Database Analysis

Favorite

8:00 AM – 6:00 PM ADT

(172) Impact of Early palliative care on humanistic outcomes in patients with advanced cancer

Favorite

8:00 AM – 6:00 PM ADT

(173) Risk Factors Associated with Long bone Fracture Non-Union – A US Claims Database Analysis

Favorite

8:00 AM – 6:00 PM ADT

(174) Prevalence of syphilis risk factors in Colorado from 2010-2020

Favorite

8:00 AM – 6:00 PM ADT

(175) Burden of Narcolepsy from the Perspectives of Direct Medical Cost and Comorbidity in Japan

Favorite

8:00 AM – 6:00 PM ADT

(176) Compare the generalizability of dapagliflozin and empagliflozin heart failure phase 3 trials to real-world patients in Taiwan

Favorite

8:00 AM – 6:00 PM ADT

(177) Utilisation and Safety of IV Bolus Formulation of Akis® for use in the Prevention and Treatment of Post-operative Pain in the UK Secondary Setting

Favorite

8:00 AM – 6:00 PM ADT

(178) Evaluation of Years of Potential Productive Life Lost (YPPLL) due to Premature Mortality from Head and Neck Cancer in Northeast India

Favorite

8:00 AM – 6:00 PM ADT

(179) Utilization and evaluation of Drug therapy usage among neonates admitted to Neonatal Intensive Care Unit (NICU)

Favorite

8:00 AM – 6:00 PM ADT

(180) Determination of patients’ quality of life (QOL) and its influencing risk factors associated with QOL in patients with autoimmune systemic vasculitis: a cross-sectional study

Favorite

8:00 AM – 6:00 PM ADT

(181) Utilization of Comprehensive Metabolic Panels in Regular Patient Management: Investigation of Patient Follow-up Based on Abnormal Test results in a Claims Laboratory Test Result Database

Favorite

8:00 AM – 6:00 PM ADT

(182) Characterizing Real-World Data Usage for Public Health Research

Favorite

8:00 AM – 6:00 PM ADT

(183) Cost-effectiveness analysis of ibuprofen versus indomethacin or paracetamol for the treatment of patent ductus arteriosus in preterm neonates

Favorite

8:00 AM – 6:00 PM ADT

(184) Management of cardiovascular risk in women with and without menopausal symptoms: a real-world depiction of clinical practice in the UK and France

Favorite

8:00 AM – 6:00 PM ADT

(185) Personalize My Treatment (PMT): The First Pan-Canadian Cancer Patient Databank Suitable for Generation of Oncology Real-World Insights

Favorite

8:00 AM – 6:00 PM ADT

(186) Cost‑effectiveness evaluation of add‑on dapagliflozin for heart failure with reduced ejection fraction among patients without type 2 diabetes

Favorite

8:00 AM – 6:00 PM ADT

(187) Comparing immunocompromised status algorithms: Implications for outcomes and clinical trial enrollment

Favorite

8:00 AM – 6:00 PM ADT

(188) Identifying Cytokine Release Syndrome in Retrospective Databases: A Performance Assessment of a Claims-Based Algorithm

Favorite

8:00 AM – 6:00 PM ADT

(189) Assessment of medication adherence and the impact of clinical pharmacist interventions on medication adherence among systemic lupus erythematosus patients: a prospective cohort study

Favorite

8:00 AM – 6:00 PM ADT

(190) Representativeness of race and ethnicity in Real World Data: a comparison by disease type

Favorite

8:00 AM – 6:00 PM ADT

(191) The Association Between Credit Risk Score and Major Depressive Disorder Burden Using Observed and Estimated PHQ-9 in a Real-World Cohort

Favorite

8:00 AM – 6:00 PM ADT

(192) Linear Weighting to Improve Representativeness of Patients with Type 2 Diabetes Mellitus in US Electronic Health Records

Favorite

8:00 AM – 6:00 PM ADT

(193) Patterns of Initiation and Discontinuation of Medications for Opioid Use Disorder in Commercially Insured Individuals in the US

Favorite

8:00 AM – 6:00 PM ADT

(194) Sex-Specific Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Atrial Fibrillation - A Systematic Review and Meta-Analysis

Favorite

8:00 AM – 6:00 PM ADT

(195) Ten-year landscape analysis of clinical research in Latin America: Only 6% of clinical trials make their results public

Favorite

8:00 AM – 6:00 PM ADT

(196) Racial disparities in medicine use during pregnancy: results from the NISAMI cohort

Favorite

8:00 AM – 6:00 PM ADT

(197) Impact of State-Level Abortion Hostility on Mifepristone Uptake Among an Employer-Insured Population, 2010-2020

Favorite

8:00 AM – 6:00 PM ADT

(198) Urban-Rural Differences in Mortality among Patients Receiving Buprenorphine for Opioid Use Disorder Treatment in Kentucky

Favorite

8:00 AM – 6:00 PM ADT

(199) Comparison of sociodemographic factors, health care utilisation by general practitioner visits and somatic hospital admissions, and medication use in Norway, Sweden, and Denmark

Favorite

8:00 AM – 6:00 PM ADT

(200) The Cascade of Care in Individuals Screened for Hepatitis C Virus Infection in Emergency Departments

Favorite

8:00 AM – 6:00 PM ADT

(202) Describing trends in hypertension-diabetes comorbidity in United States adults from 2008 to 2022 using Real World Data

Favorite

8:00 AM – 6:00 PM ADT

(204) The Association Between Social Determinants of Health and 1-Year Survival Among Patients with Heart Failure in a Real-World Cohort

Favorite

8:00 AM – 6:00 PM ADT

(205) Use of the web to promote antimicrobial stewardship–implementation of national AMR action plans, 2021

Favorite

8:00 AM – 6:00 PM ADT

(206) The role of gender in health inequality; will methodological standardization close this gap? Results from a pragmatic review

Favorite

8:00 AM – 6:00 PM ADT

(207) Clinical Characteristics of Patients with Different Types of Psoriasis In Optum Market Clarity Data

Favorite

8:00 AM – 6:00 PM ADT

(208) Relationship between access to medicines in the unified health system and users' perception of health in the context of the national survey on access, use and promotion of the rational use of medicines

Favorite

8:00 AM – 6:00 PM ADT

(209) Assessing “neglected populations” in clinical trials – a pilot study of asthma medication use

Favorite

8:00 AM – 6:00 PM ADT

(210) Trends in Racial Disparities for Total Knee Arthroplasty — a US Hospital Database Analysis, 2000 – 2021

Favorite

8:00 AM – 6:00 PM ADT

(211) Racial/ethnic differences in mental health service use and unmet need for treatment among US adults with a past-year major depressive episode in the 2020 National Survey on Drug Use and Health Data

Favorite

8:00 AM – 6:00 PM ADT

(212) Effect of Race on Classification of Atherosclerotic Risk Using a National Cardiovascular Risk Prediction Tool

Favorite

8:00 AM – 6:00 PM ADT

(213) Generating synthetic cohorts of real-world patients with metastatic breast cancer to accelerate collaboration

Favorite

8:00 AM – 6:00 PM ADT

(214) A Systematic Literature Review of Current Application of Machine Learning for Patient Phenotyping and Selection in Observational Studies

Favorite

8:00 AM – 6:00 PM ADT

(215) Examining misclassification differences for myocardial infarction and angioedema between drug exposures

Favorite

8:00 AM – 6:00 PM ADT

(217) Development of Computable Operational Definitions to Maximize Comparability & Consistency Across a Multi-Data Source Global Real-World Effectiveness Program

Favorite

8:00 AM – 6:00 PM ADT

(218) Methodological challenges for single- vs polydrug classification of drug overdose deaths

Favorite

8:00 AM – 6:00 PM ADT

(219) Development of Audit Readiness Considerations of Real-World Data for Use in Regulatory Decision-Making

Favorite

8:00 AM – 6:00 PM ADT

(220) The Utility and Versatility of Linked Database in HIV Care for tracking Vertical Transmission of HIV in the Western Cape Province in South Africa

Favorite

8:00 AM – 6:00 PM ADT

(221) Methods in Dynamic Treatment Regimens using Observational Data: A Systematic Review

Favorite

8:00 AM – 6:00 PM ADT

(222) Evaluation of tokenization using a large claims and medical records dataset in patients with hemophilia B

Favorite

8:00 AM – 6:00 PM ADT

(223) Evaluation of the completeness of a medical record dataset linked to administrative claims through tokenization in patients with hemophilia B

Favorite

8:00 AM – 6:00 PM ADT

(224) Sub-Analyses, Post-Hoc Analyses and Full Publication Rate: Are we Potentially Missing Important Evidence?

Favorite

8:00 AM – 6:00 PM ADT

(225) Bibliometric Analysis Based on Abstracts of the 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management

Favorite

8:00 AM – 6:00 PM ADT

(226) Data Stewardship and its Role in Ensuring Real-World Data Quality and Methodological Rigor in Research

Favorite

8:00 AM – 6:00 PM ADT

(227) Severity and burden of sickle cell disease (SCD) in France: a nationwide real-world study

Favorite

8:00 AM – 6:00 PM ADT

(228) Development of a risk categorization framework to quantify antimicrobial resistance risk in female patients with uncomplicated urinary tract infection

Favorite

8:00 AM – 6:00 PM ADT

(229) Artificial intelligence applied: data-driven vector representations of adverse events and drugs in pharmacovigilance

Favorite

8:00 AM – 6:00 PM ADT

(230) Risk of Electrolyte Imbalance in Elderly Colorectal Cancer Patients Following Treatment with Metformin Vs Sulfonylureas

Favorite

8:00 AM – 6:00 PM ADT

(231) Bespoke Code vs. Off-the-shelf R Package in Calculating Incidence Rates Using Real-World Data

Favorite

8:00 AM – 6:00 PM ADT

(232) Diversifying the FDA’s Sentinel System with Rigorous Quality Inclusion Rules for the U.S. Medicaid Population

Favorite

8:00 AM – 6:00 PM ADT

(233) Identification of Unrecognized Associations Between Medications and Gastrointestinal Bleeding by Screening Large Administrative Health Data

Favorite

8:00 AM – 6:00 PM ADT

(234) Developing a perinatal extension for the OMOP common data model

Favorite

8:00 AM – 6:00 PM ADT

(235) Characterizing Disease Progression in Multiple Sclerosis Subtypes Using RWD: Feasibility of Applying a Machine Learning Model to Address Missing Data

Favorite

8:00 AM – 6:00 PM ADT

(236) New Approaches for Linking Mother and Infant Data using Electronic Medical Records Data

Favorite

8:00 AM – 6:00 PM ADT

(237) Lift Off: From Real World Data Quality Guidelines to Actionable Assessment

Favorite

8:00 AM – 6:00 PM ADT

(239) Novel Data and Lag-times within the EHR Provided by the Long-Term Care Data Cooperative (LTCDC)

Favorite

8:00 AM – 6:00 PM ADT

(240) Characterization of Real World data sources for pharmacoepidemiological studies in pregnancy and lactation: the ConcePTION project

Favorite

8:00 AM – 6:00 PM ADT

(241) Unlocking the patient journey: comparing machine learning (ML) based natural language processing (NLP) and expert abstraction in understanding treatment patterns

Favorite

8:00 AM – 6:00 PM ADT

(243) Feasibility Assessment of a Real-world Clinico-genomics Dataset in Non-small Cell Lung Cancer (AACR GENIE BPC)

Favorite

8:00 AM – 6:00 PM ADT

(245) Evaluation of Handling Degrees of Missingness in the Features of Machine Learning Algorithms to Predict Overall Survival Using Real-World Lung Cancer Data

Favorite

8:00 AM – 6:00 PM ADT

(246) Real-world evidence on the burden of known side-effects of typical and atypical antipsychotic medications in patients with schizophrenia

Favorite

8:00 AM – 6:00 PM ADT

(247) Validating Type II Diabetes Case Definitions in Electronic Health Records: A Comparison of Sensitivity and Specificity Using HbA1c as the Gold Standard

Favorite

8:00 AM – 6:00 PM ADT

(248) A novel approach to secondary data studies in pregnancy leveraging linked EMRs linked under Health Information Exchanges in the Unites States

Favorite

8:00 AM – 6:00 PM ADT

(249) Detecting digital illness threat using an anomaly detection approach in the United States

Favorite

8:00 AM – 6:00 PM ADT

(251) NLP Detection of Mortality Information from Publicly Available Data using Deep Learning Modelling

Favorite

8:00 AM – 6:00 PM ADT

(252) Assessing validity of privacy-preserving synthetic patient data: A use case utilizing Israel COVID-19 real-world vaccine effectiveness study

Favorite

8:00 AM – 6:00 PM ADT

(253) An Emulated Target Trial Case Study of Real-World Overall Survival in Second-line Maintenance Niraparib vs Active Surveillance in Patients with Recurrent Ovarian Cancer

Favorite

8:00 AM – 6:00 PM ADT

(254) Prevalence and prognosis of hypoxia-inducible factor-2α (HIF-2α) pathway gene mutations across tumor types

Favorite

8:00 AM – 6:00 PM ADT

(255) Biomarkers Predictive of a Response to Extended Endocrine Therapy in Breast Cancer: A Systematic Review

Favorite

8:00 AM – 6:00 PM ADT

(256) Dealing with time-varying treatments in observational studies: a qualitative methodological review and proposal of research framework

Favorite

8:00 AM – 6:00 PM ADT

(258) Evaluating the impact of 5-HTTLPR on metformin response in type II diabetes patients in a longitudinal cohort study

Favorite

8:00 AM – 6:00 PM ADT

(259) Non-squamous, Metastatic Non-small Cell Lung Cancer: Retrospective c-Met Overexpression Testing, Patient Characteristics, and Treatment Patterns

Favorite

8:00 AM – 6:00 PM ADT

(260) Characterizing the Distribution of Multiple Negative Control Outcome Risk Differences

Favorite

8:00 AM – 6:00 PM ADT

(261) CARMA-BROS: An efficient Basket/Umbrella Real-world Observational Study (BUROS) Design for Rare Cancer Subtypes

Favorite

8:00 AM – 6:00 PM ADT

(262) The diagnostic landscape of HRD testing based on cross-sectional survey of physicians and molecular biologists conducting testing (INDICATOR ONE)

Favorite

8:00 AM – 6:00 PM ADT

(263) EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois: CONTACT: Recruiting and Engaging Participants

Favorite

8:00 AM – 6:00 PM ADT

(265) Effect of CYP and NAT2 Gene Polymorphisms on Human Response to Artemisinin-Based Combination Therapies in Yaounde, Cameroon

Favorite

8:00 AM – 6:00 PM ADT

(266) BMP8B: A beacon of hope for a non-invasive diagnostic biomarker of NAFLD progression

Favorite

8:00 AM – 6:00 PM ADT

(267) Unbalanced microbial genomic sequences from East Africa limits global surveillance for antimicrobial resistance in non-typhoidal Salmonella

Favorite

8:00 AM – 6:00 PM ADT

(268) Issues of statine utilisation

Favorite

8:00 AM – 6:00 PM ADT

(269) Integration of Basket/Umbrella Real-world Observational Studies (BUROS) into International Epidemiological Consortia to Inform Cancer Clinical Course and Disease Epidemiology

Favorite

8:00 AM – 6:00 PM ADT

(270) Building Fit-For-Purpose Real-World Clinicogenomic Data in Aesthetics for Personalized Skin Care Goals

Favorite

8:00 AM – 6:00 PM ADT

(271) Interferon-beta exposure in-utero and the risk of infections

Favorite

8:00 AM – 6:00 PM ADT

(272) Changes in Pediatric Emergency Department Visits and Hospitalizations for Unintentional Exposures to Oral Prescription Medications in the United States, 2010-2021

Favorite

8:00 AM – 6:00 PM ADT

(273) Validation of ICD-9- and ICD-10-based Diagnostic Algorithms for Juvenile Idiopathic Arthritis within a Large U.S. Commercial Claims Database

Favorite

8:00 AM – 6:00 PM ADT

(275) Sex-specific prevalences of psychotropic medication in pediatric populations from DK and US: 2010-2020

Favorite

8:00 AM – 6:00 PM ADT

(276) Medical cannabis related drug-drug interactions in children: A systematic review

Favorite

8:00 AM – 6:00 PM ADT

(277) Sociodemographic and birth characteristics associated with initiation of methylphenidate treatment in children: a nationwide study from 2015 to 2022

Favorite

8:00 AM – 6:00 PM ADT

(278) Utilisation and safety of Glycopyrronium Bromide 1mg/5ml oral solution for sialorrhoea in the paediatric population in the UK: Interim results from a non-interventional post authorisation safety study

Favorite

8:00 AM – 6:00 PM ADT

(279) First-Line Treatments for Infantile Spasms: A GRADE Analysis of Umbrella Review of Systematic Reviews and Meta-Analyses

Favorite

8:00 AM – 6:00 PM ADT

(280) Comparison of presepsin and interleukin 6 for the diagnosis of neonatal sepsis: a systematic review and meta-analysis

Favorite

8:00 AM – 6:00 PM ADT

(282) Pediatric observational effectiveness evaluation studies in the EU PAS Register: What can we learn from study characteristics?

Favorite

8:00 AM – 6:00 PM ADT

(284) Trend analysis of medication label prediction model based on real-world pediatric drug database

Favorite

8:00 AM – 6:00 PM ADT

(285) Real-world Data Evaluating Safety, Effectiveness and Dosing of Dalteparin for the Treatment of Venous Thromboembolism (VTE) in Neonates Aged 0 to 28 days

Favorite

8:00 AM – 6:00 PM ADT

(286) Accuracy of ICD-10 Diagnosis Codes for Identifying Influenza Illness Among Children in the Emergency Department and Hospital Settings

Favorite

8:00 AM – 6:00 PM ADT

(287) Assessing neonatal outcome misclassification using mother-infant dyad claims

Favorite

8:00 AM – 6:00 PM ADT

(B01) Adherence and persistence to cardiovascular medicines in Australia among people initiating therapy in 2018

Favorite

8:00 AM – 6:00 PM ADT

(B02) Adherence to hypoglycemic medications among pregnant patients with gestational diabetes

Favorite

8:00 AM – 6:00 PM ADT

Favorite

8:00 AM – 6:00 PM ADT

(B04) Direct Medical Cost Associated with Antiplatelet Non-persistence in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention

Favorite

8:00 AM – 6:00 PM ADT

(B05) Effectiveness of Medication Therapy Management in Older Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Favorite

8:00 AM – 6:00 PM ADT

(B06) Evaluate Medication Adherence Classes using Latent Mixed Model

Favorite

8:00 AM – 6:00 PM ADT

(B07) Exploring Real-life Persistence with Denosumab (Prolia®): A 7-year-follow-up Study In Spain

Favorite

8:00 AM – 6:00 PM ADT

(B08) Older adults’ adherence to medications and willingness to deprescribe: A sub-study of a randomized clinical trial

Favorite

8:00 AM – 6:00 PM ADT

(B09) A Hospital-Based Cohort Study on Drug-Related Problems Associated with High-Risk Medications Amongst Special Populations

Favorite

8:00 AM – 6:00 PM ADT

(B10) Comparison of common protocol vs. common data model and the issues of analytic inconsistency for a multi-database pharmacoepidemiologic study

Favorite

8:00 AM – 6:00 PM ADT

(B11) Comparisons of non-vitamin K antagonist oral anticoagulants and warfarin for incident depressive disorders in patients with atrial fibrillation: A nationwide cohort study using target trial emulation framework

Favorite

8:00 AM – 6:00 PM ADT

(B12) Effect of Bisphosphonates versus Denosumab on Risks of Cardiovascular Events in Patients with Type 2 Diabetes

Favorite

8:00 AM – 6:00 PM ADT

(B13) Evaluation Suboptimal Outcomes in Crohn's Disease Patients with Biologic Treatment

Favorite

8:00 AM – 6:00 PM ADT

(B14) Risk of Ischemic or Hemorrhagic Retinopathy and Anticholinergic Burden in Elderly Patient in Taiwan: A Case-Crossover Study

Favorite

8:00 AM – 6:00 PM ADT

(B15) Use of Different Antihypertensive Drugs and Risk of Intradialytic Hypotension in Patients Undergoing Hemodialysis

Favorite

8:00 AM – 6:00 PM ADT

(B16) Immunization Status of the 23-Valent Pneumococcal Polysaccharide Vaccine among Elderly Aged 65 and Older in South Korea

Favorite

8:00 AM – 6:00 PM ADT

(B17) Comparison of biologic use in pivotal clinical trials vs. real-world setting with immune-mediated inflammatory diseases: an Italian population-based study from the VALORE project

Favorite

8:00 AM – 6:00 PM ADT

(B18) Comparison of Serious Infections between Biosimilar and Bio-Originator Initiators in Canada: Population-Based Analyses

Favorite

8:00 AM – 6:00 PM ADT

(B19) Disease severity profile and treatment switch patterns as treatment response proxy in Crohn’s disease population using Optum databases

Favorite

8:00 AM – 6:00 PM ADT

(B20) Impact of COVID Lock-down on Adherence to Romosozumab Among US Post-menopausal Women Enrolled in Medicare

Favorite

8:00 AM – 6:00 PM ADT

(B21) Joint pain in patients with atopic dermatitis receiving treatment with dupilumab in a nation-wide cohort study

Favorite

8:00 AM – 6:00 PM ADT

(B23) Rates of Intraocular Inflammation Following Intravitreal Aflibercept Prefilled Syringe and Vial Injections in US Clinical Practice, 2014-2022

Favorite

8:00 AM – 6:00 PM ADT

(B24) Risk of Venous Thromboembolism with Janus Kinase Inhibitors in Rheumatoid Arthritis: A Systematic Review

Favorite

8:00 AM – 6:00 PM ADT

(B25) A Digital Toolkit to Contextualise and Visualise the Benefit and Risk of COVID-19 Vaccines in the European Union

Favorite

8:00 AM – 6:00 PM ADT

(B26) Assessment of the U.S. Food and Drug Administration’s Risk Evaluation and Mitigation Strategy (REMS) for Prasugrel (Effient)

Favorite

8:00 AM – 6:00 PM ADT

(B27) Communicating Drug Safety and Safe Use Conditions in Risk Evaluation and Mitigation Strategy Materials

Favorite

8:00 AM – 6:00 PM ADT

(B28) Physician Knowledge of Safe Use of Cyproterone Acetate Monotherapies and Meningioma

Favorite

8:00 AM – 6:00 PM ADT

(B29) The Use of Statins for the Primary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: A Quantitative Benefit-Risk Analysis

Favorite

8:00 AM – 6:00 PM ADT

(B30) Utility of Healthcare Professional (HCP) Surveys for Evaluating the Effectiveness of Additional Risk Minimization Measures (aRMMs): Experience from an HCP Survey Assessing the Effectiveness of aRMMs for Xeljanz® in Europe

Favorite

8:00 AM – 6:00 PM ADT

(B31) What are patient with non-small cell lung cancer (NSCLC) preferences regarding treatment?

Favorite

8:00 AM – 6:00 PM ADT

(B32) What do we know on patient preferences for treatment of multiple sclerosis?

Favorite

8:00 AM – 6:00 PM ADT

(B34) Examining the risk of COVID-19 among cancer patients and comparing it with the Swedish general population: A register-based cohort study within the SCIFI-PEARL project

Favorite

8:00 AM – 6:00 PM ADT

(B35) Glucagon Like Peptide-1 Receptor Agonists and the Risk of Skin Cancer Among Patients with Type 2 Diabetes: Population-Based Cohort Study

Favorite

8:00 AM – 6:00 PM ADT

(B36) Predicting HER2 Status in Non-Small Cell Lung Cancer using Machine Learning Approach for Precision Cancer Pharmacoepidemiology in Large Databases

Favorite

8:00 AM – 6:00 PM ADT

(B37) Predictive Biomarkers for PD-1/PD-L1 Checkpoint Inhibitor Response in NSCLC – an Analysis of Clinical Trial and Real-world Data

Favorite

8:00 AM – 6:00 PM ADT

(B39) Trends in New and Persistent Opioid Use in Older Adults with Cancer

Favorite

8:00 AM – 6:00 PM ADT

(B40) When does the clock start ticking? Deriving the date of cancer diagnosis from electronic health record data

Favorite

8:00 AM – 6:00 PM ADT

(B41) A Framework for Considering Regulatory Likelihood of Acceptance of a Single-Arm Trial

Favorite

8:00 AM – 6:00 PM ADT

(B42) A retrospective cohort study of Gaucher Disease Type 1 to describe sub-optimal responders to standard of care treatments in the United States

Favorite

8:00 AM – 6:00 PM ADT

(B43) A systematic review of the efficacy of sirolimus and methotrexate after hematopoietic stem cell transplantation

Favorite

8:00 AM – 6:00 PM ADT

(B44) Assessing Risk of Bias in Comparative Effectiveness Studies of Chimeric Antigen Receptor T-Cell Therapies for Relapsed or Refractory Large B-Cell Lymphoma

Favorite

8:00 AM – 6:00 PM ADT

(B45) Feasibility of Assessing Comparative Long-Term Safety for Gene Therapy Products by Creating an External Control Arm using Real-World Data Sources

Favorite

8:00 AM – 6:00 PM ADT

(B46) Maximising the use of real-world data from multiple sources to generate comprehensive evidence: insights from retrospective cohorts of allogeneic hematopoietic cell transplant recipients with adenovirus infection

Favorite

8:00 AM – 6:00 PM ADT

(B47) Cardiovascular risk stratification in patients with type 2 diabetes

Favorite

8:00 AM – 6:00 PM ADT

(B48) Causal forests vs Inverse probability weighting for addressing cluster-level confounding in medical device and surgical epidemiology: A simulation study

Favorite

8:00 AM – 6:00 PM ADT

(B49) Comparative cardiovascular effectiveness of liraglutide 3 mg

Favorite

8:00 AM – 6:00 PM ADT

(B50) Comparing approaches to achieving exact balance on key covariates in propensity score matched analyses: a simulation study

Favorite

8:00 AM – 6:00 PM ADT

(B51) Immortal time bias arising from inappropriate anchor of outcome event date

Favorite

8:00 AM – 6:00 PM ADT

(B52) Preventing Heart Failure Admissions with Sodium-Glucose Cotransporter-2 Inhibitors versus Angiotensin Receptor-Neprilysin Inhibitors: A Target Trial Emulation Study

Favorite

8:00 AM – 6:00 PM ADT

(B53) Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population-based cohort study

Favorite

8:00 AM – 6:00 PM ADT

(B54) Variance Estimation of the Risk Difference When Using Propensity-Score Matching and Weighting with Time-To-Event Outcomes

Favorite

8:00 AM – 1:30 PM ADT

(001) Evaluation Of The Potential Rebound Effect Of Denosumab Discontinuation: A Comparative Study Of Five Different Types Of Antiosteoporotic Medications

Favorite

8:00 AM – 1:30 PM ADT

(002) Challenges and future perspectives of enhanced passive safety surveillance (EPSS) of influenza vaccines in Europe

Favorite

8:00 AM – 1:30 PM ADT

(003) Clinical Harms Associated with Xylazine Use in Humans

Favorite

8:00 AM – 1:30 PM ADT

(004) Mapping the Information Pathways of Adverse Reactions Through Clinical Event Sequences, Patient Interactions with the Healthcare System and Generation of Different Data Streams – a Qualitative Pilot Study

Favorite

8:00 AM – 1:30 PM ADT

(005) A Real-world Evidence on Electrolyte Disorders with Piperacillin/Tazobactams :Using the FARES Database over 10 years

Favorite

8:00 AM – 1:30 PM ADT

(006) Trends and Patterns of the Reported Antimicrobial Errors to the Eastern Region’s Medical Centers in Saudi Arabia: A Cross-Sectional Study

Favorite

8:00 AM – 1:30 PM ADT

(007) Characterization of Japanese Risk Management Plans Using Automatically Extracted Information by Robotic Process Automation Tool

Favorite

8:00 AM – 1:30 PM ADT

(008) Hypersensitivity Reactions with Ultrasound Contrast Agents in Patients with a History of Polyethylene Glycol Allergy

Favorite

8:00 AM – 1:30 PM ADT

(009) Pharmacovigilance of pharmaceutical products in colorectal cancer: a systematic review and metanalysis

Favorite

8:00 AM – 1:30 PM ADT

(010) Comparing the Efficacy and Safety of Dolutegravir and Efavirenz-based Antiretroviral Regimens: A Retrospective Study

Favorite

8:00 AM – 1:30 PM ADT

(011) Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: a cohort study

Favorite

8:00 AM – 1:30 PM ADT

(012) Safety of using nirmatrelvir/ritonavir and cardiovascular medications with potential drug-drug interactions: Comparative safety analysis using WHO international database

Favorite

8:00 AM – 1:30 PM ADT

(013) Risk of gastrointestinal bleeding associated with antiviral treatment among influenza patients

Favorite

8:00 AM – 1:30 PM ADT

(014) Association between use of fluoroquinolones and risk of mitral or aortic valve regurgitation: a population-based cohort study

Favorite

8:00 AM – 1:30 PM ADT

(015) In-utero azathioprine exposure and neurodevelopmental disorders in the offspring

Favorite

8:00 AM – 1:30 PM ADT

(016) Cardiovascular Adverse Events associated with JAK Inhibitor versus TNF Inhibitor: A Disproportionality Analysis in National Pharmacovigilance Database of Korea

Favorite

8:00 AM – 1:30 PM ADT

(017) Cohort Study of Serious Angioedema in Association with Sacubitril/Valsartan Use in Black Patients with Heart Failure

Favorite

8:00 AM – 1:30 PM ADT

(018) Interaction Between Cannabis And Cytochromes P450 Substrates: Potential Safety Signals from a Disproportionality Analysis Using the US Food And Drug Administration Adverse Event Reporting System Database

Favorite

8:00 AM – 1:30 PM ADT

(019) A new tool to estimate comorbidities at the population-level in the United States

Favorite

8:00 AM – 1:30 PM ADT

(020) Association between Cumulative Corticosteroid Dose and Risk of Avascular Necrosis in patients with Systemic Lupus Erythematosus : A nested case-control study

Favorite

8:00 AM – 1:30 PM ADT

(021) Aspirin and non-aspirin antiplatelet agents use and risk of ischemic and hemorrhagic stroke in patients with non-valvular atrial fibrillation with and without anticoagulant therapy: a case-referent study

Favorite

8:00 AM – 1:30 PM ADT

(022) Temporal Trends in Adverse Drug Reactions Reports of Medicines for Treating Human Immunodeficiency Virus and Tuberculosis, and All Diseases: Joinpoint Regression

Favorite

8:00 AM – 1:30 PM ADT

(023) The Impact of the Removal of Liver Injury Warning and Liver Testing Requirement on Ambrisentan Use and Liver Function Testing

Favorite

8:00 AM – 1:30 PM ADT

(025) Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022

Favorite

8:00 AM – 1:30 PM ADT

(026) Adverse Drug Reaction Reporting Among Nurses in Nigeria: Opinion Survey of Their Knowledge, Attitude, and Practice

Favorite

8:00 AM – 1:30 PM ADT

(027) Factors linked to hospital-admission of chronic non-cancer pain patients prescribed long-term strong opioids

Favorite

8:00 AM – 1:30 PM ADT

(028) Development and Implementation of the National Clozapine Safety System for the Department of Veterans Affairs

Favorite

8:00 AM – 1:30 PM ADT

(029) Characterizing of adverse events across 30,000 peer reviewed case report publications

Favorite

8:00 AM – 1:30 PM ADT

(030) Development and validation of technology assisted tool for Data mining of public version of FAERS database using python language

Favorite

8:00 AM – 1:30 PM ADT

(031) Medical Scandal with illegally diluted Chemotherapy in Germany: Prognosis of Patients with Breast and non-solid Cancers

Favorite

8:00 AM – 1:30 PM ADT

(032) Exploring the Use of Electronic Health Records (EHR) Data for Active Safety Surveillance of Epidiolex in PCORnet, July 1, 2018- July 1, 2022

Favorite

8:00 AM – 1:30 PM ADT

(033) Prescription Sequence Symmetry Analysis of Administrative Claims Data for Detection of Opioid Use Adverse Events

Favorite

8:00 AM – 1:30 PM ADT

(034) Relationship Between Misuse of Substances and Abuse as Reported in the FDA FAERS data

Favorite

8:00 AM – 1:30 PM ADT

(035) Medication Safety Stewardship in Antibiotic usage in Critical Care Units

Favorite

8:00 AM – 1:30 PM ADT

(036) Physician Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies: Results from a National Survey

Favorite

8:00 AM – 1:30 PM ADT

(037) Is aggregate use of published case reports as a viable option for augmenting pharmacovigilance? An applied example of pembrolizumab-related adverse events in non-small cell lung cancer patients receiving first-line treatment

Favorite

8:00 AM – 1:30 PM ADT

(038) Risk of Cholelithiasis and Cholecystitis for antidiabetic medications: Evidence synthesis from a disproportionality analysis

Favorite

8:00 AM – 1:30 PM ADT

(039) RAAS Inhibitors-Related Adverse Drug Reactions and the Risk of Subsequent Cardiovascular Event and All-Cause Mortality: A Cohort Study in UK Primary Care

Favorite

8:00 AM – 1:30 PM ADT

(040) Bleeding related adverse events associated with antiviral treatment in influenza patients: a disproportionality analysis using FDA adverse event reporting system (FAERS)

Favorite

8:00 AM – 1:30 PM ADT

(041) Budsinfo: A User-Friendly Platform for Reporting the Effects of Cannabis and Hemp-Derived Products

Favorite

8:00 AM – 1:30 PM ADT

(042) Laboratory screening tests before and during the use of systemic immunomodulatory agents in patients with chronic inflammatory skin diseases

Favorite

8:00 AM – 1:30 PM ADT

(043) Health Canada’s Vigilance Framework for Cannabis: A summary of adverse reactions associated with cannabis products

Favorite

8:00 AM – 1:30 PM ADT

(044) Open insurance claims database vs closed insurance claims database to support pharmacovigilance review of potential safety event in patients with B-cell malignancies: a fit for purpose evaluation

Favorite

8:00 AM – 1:30 PM ADT

(045) Impact of European Union label changes to avoid inadvertent use of once-weekly methotrexate: A cross-sectional survey amongst prescribers, pharmacists and patients on awareness, knowledge, and behaviour

Favorite

8:00 AM – 1:30 PM ADT

(046) Extent of apremilast exposure misclassification in CPRD Aurum: a validation study

Favorite

8:00 AM – 1:30 PM ADT

(047) Technology Aided Intervention to Improve the Metabolic Monitoring Rate in Patients on Atypical Antipsychotics

Favorite

8:00 AM – 1:30 PM ADT

(048) Quality compliance while conducting NIS studies: critical success factors assessment and the use of key performance indicators

Favorite

8:00 AM – 1:30 PM ADT

(049) Poisonings with Antidepressants in Relation to Prescriptions; Venlafaxine and Amitriptyline Stands Out

Favorite

8:00 AM – 1:30 PM ADT

(050) A Qualitative Approach in Assessing the Contributing Factors towards the Medication Error-Prone Behavior amongst the Healthcare Professionals

Favorite

8:00 AM – 1:30 PM ADT

(051) Monitoring of adverse events during seasonal malaria chemoprevention campaigns in children aged 3-59 months in Burkina Faso: A real-world evidence

Favorite

8:00 AM – 1:30 PM ADT

(052) Initiation and Implementation of a Medication Error Reporting and Monitoring Program: A Developing Country Scenario

Favorite

8:00 AM – 1:30 PM ADT

(053) Proton pump inhibitors and risk of kidney diseases: An overview of meta-analyses

Favorite

8:00 AM – 1:30 PM ADT

(054) Supporting pharmacovigilance signal validation and prioritisation with analyses of routinely collected health data – lessons learned from an EHDEN network study

Favorite

8:00 AM – 1:30 PM ADT

(055) Psychological and Neurological Adverse Drug Events Associated with Direct Acting Antivirals Agents Used for Hepatitis C Virus: Analysis and Comparison of the FDA Adverse Event Reporting System (FAERS) and Lexicomp

Favorite

8:00 AM – 1:30 PM ADT

(056) A Novice Stratagem in the Quantification of the Contributing Factors Associated to Medication Errors

Favorite

8:00 AM – 1:30 PM ADT

(058) Impact of Educational Awareness on Knowledge and Attitude of ADR Reporting Among Medical, Pharmacy, Dentistry and Nursing Students: An Interventional Study

Favorite

8:00 AM – 1:30 PM ADT

(059) Classifying Chemotherapy Chaos: Navigating Blood & Lymphatic Side Effects

Favorite

8:00 AM – 1:30 PM ADT

(060) Rapid Use of Real-World Data in Safety Signal Assessment

Favorite

8:00 AM – 1:30 PM ADT

(062) Fatal tramadol intoxications in Sweden, almost 50% of the individuals lacked a prescription

Favorite

8:00 AM – 1:30 PM ADT

(063) Causality assessment of adverse drug reactions in post-authorization settings: An analysis from four different countries to find out the most comprehensive and easy-to-use tool

Favorite

8:00 AM – 1:30 PM ADT

(064) Capecitabine-Induced Adverse Reactions in Patients with Biliary Tract Cancer: Evidence from Spontaneous Reporting Data Analysis and Systematic Review & Meta-Analysis

Favorite

8:00 AM – 1:30 PM ADT

(065) Potential Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions(DDIs) of QT Prolonging Drugs in a cohort of Psychiatry Patients

Favorite

8:00 AM – 1:30 PM ADT

(067) Uncovering the Skin Reactions: Retrospectively Analyzing the Adverse Drug Reactions Related to Skin & Subcutaneous Tissues disorders

Favorite

8:00 AM – 1:30 PM ADT

(068) Descriptive Analysis of Safety of Ketamine Utilizing FDA Adverse Events Reporting System FAERS Database

Favorite

8:00 AM – 1:30 PM ADT

(069) Sociodemographic Factors Affecting Drug Interactions in Stable Angina Pectoris Patients in the Cardiology Polyclinic of A Tertiary General Hospital in Banjarmasin

Favorite

8:00 AM – 1:30 PM ADT

(070) Application of machine learning methods in risk assessment of fracture associated with antihypertensives in older people with a large number of confounders

Favorite

8:00 AM – 1:30 PM ADT

(071) Drug Plan Monitoring of Paxlovid Adherence and Patient-Reported Adverse Events in British Columbia

Favorite

8:00 AM – 1:30 PM ADT

(072) Association between Mortality and Cumulative Exposure to Antipsychotics, Antidepressants and Benzodiazepines in Patients with Schizophrenia: A Real-World Observational Study

Favorite

8:00 AM – 1:30 PM ADT

(073) Purine antimetabolites associated pneumocystis jiroveci pneumonia among autoimmune and cancer population

Favorite

8:00 AM – 1:30 PM ADT

(074) Active and Passive Safety Surveillance in Children Receiving Live Attenuated Influenza Vaccine (LAIV), in England During Early Influenza Seasons from 2014/2015 to 2021/2022

Favorite

8:00 AM – 1:30 PM ADT

(075) Reasons for Treatment Alteration in Dermatology Patients: Insights from Unstructured Clinical Notes

Favorite

8:00 AM – 1:30 PM ADT

(076) Drug Repurposing for Hepatocellular Carcinoma via Real World Data Corroborated with Bioinformatics

Favorite

8:00 AM – 1:30 PM ADT

(077) A Canadian Approach to Classifying Acute Kidney Injury and Other Reports of Renal Adverse Events of Interest Following Immunization

Favorite

8:00 AM – 1:30 PM ADT

(078) Perception of Facilitators and Barriers to Strengthen restriction of non-medical use opioid prescription among healthcare practitioner in China: a qualitative study

Favorite

8:00 AM – 1:30 PM ADT

(079) Graph Machine Learning in Adverse Events Safety Signal Management: A Research Proposal

Favorite

8:00 AM – 1:30 PM ADT

(080) Identification of a novel signal congenital scoliosis for zopiclone through FDA FAERS database

Favorite

8:00 AM – 1:30 PM ADT

(081) Active surveillance and evaluation of anosmia/ageusia following mRNA-1273 administration: Learnings from a US administrative claims database study

Favorite

8:00 AM – 1:30 PM ADT

(083) Treatment Patterns Before, During, and After Pregnancy in Inflammatory Bowel Disease

Favorite

8:00 AM – 1:30 PM ADT

(084) Patterns of antiseizure medications prescriptions among pregnant people with epilepsy: a utilization study in three Canadian provinces

Favorite

8:00 AM – 1:30 PM ADT

(085) Trends and patterns of antiseizure medication prescribing during pregnancy between 1995 and 2018 in the United Kingdom

Favorite

8:00 AM – 1:30 PM ADT

(086) Trends in the Use of Prescription Medications Among Women of Reproductive Age by Pregnancy Status in the U.S., 2009-2020

Favorite

8:00 AM – 1:30 PM ADT

(087) Characteristics and Outcomes of Pregnant Patients and Their Infants in a Linked Maternal-Infant Administrative Claims Database

Favorite

8:00 AM – 1:30 PM ADT

(088) Changes in Diclectin Utilization Trends in Ontario Following Media Attention: A Time-Series Analysis

Favorite

8:00 AM – 1:30 PM ADT

(089) Application of a Structured Process to Identify Fit-for-Purpose Data for Pregnancy Database Study

Favorite

8:00 AM – 1:30 PM ADT

(090) Use of Medication for Gastroesophageal Reflux During Pregnancy and Adverse Birth Outcomes

Favorite

8:00 AM – 1:30 PM ADT

(091) Abortion-related Trends Before and After the Dobbs Decision within TriNetX Electronic Medical Record Data

Favorite

8:00 AM – 1:30 PM ADT

(092) Trends in Medically Assisted Reproduction Utilization and Obstetrical as well as Perinatal Outcomes in Quebec between 2005 and 2015 - the Impact of the Universal Access Program: an interrupted time series analysis

Favorite

8:00 AM – 1:30 PM ADT

(093) Expanding Pregnancy Surveillance Programs to Assess Effects of Medicinal Product Exposure During Lactation

Favorite

8:00 AM – 1:30 PM ADT

(094) A first step in drug utilisation and safety studies: identifying indications for drug use in administrative data sources. A pilot study with gabapentinoids in a French healthcare data source. A contribution from the ConcePTION project

Favorite

8:00 AM – 1:30 PM ADT

(095) Utilization of prescribed drugs in pregnancy between 2015 and 2021 in Switzerland: A retrospective analysis of Swiss healthcare claims data

Favorite

8:00 AM – 1:30 PM ADT

(096) Medications considered to have substantial teratogenic risk commonly used in US pregnant population – quality of evidence and magnitude of risk

Favorite

8:00 AM – 1:30 PM ADT

(097) Lactation Studies: When are healthy volunteers an option?

Favorite

8:00 AM – 1:30 PM ADT

(098) Exposure to teratogens in pregnancy and in women of childbearing age between 2015 and 2021 in Switzerland: A retrospective analysis of Swiss healthcare claims data

Favorite

8:00 AM – 1:30 PM ADT

(099) Patterns of prescription medication use during pregnancy in the United States, 1997–2018

Favorite

8:00 AM – 1:30 PM ADT

(100) A Systematic Review of Secondary Databases Used in Paternal Drug Exposure Studies and Discussion of Paternal Exposure Related Pregnancy Outcomes

Favorite

8:00 AM – 1:30 PM ADT

(101) Drug utilisation studies in pregnant women for newly licensed medicinal products: reflections from IMI-ConcePTION

Favorite

8:00 AM – 1:30 PM ADT

(102) Development of Drug Trees to Support TreeScan Analyses of Prenatal Drug Exposures Associated with Fetal Cardiac Malformations

Favorite

8:00 AM – 1:30 PM ADT

(103) Identification of Pregnancies Without a Recorded Outcome in German Claims Data

Favorite

8:00 AM – 1:30 PM ADT

(104) Antiseizure medication use in pregnancy and adverse neonatal birth outcomes: a population-based cohort study

Favorite

8:00 AM – 1:30 PM ADT

(105) Real-world prenatal exposure to topiramate among women of childbearing age and their contraceptive use in the USA

Favorite

8:00 AM – 1:30 PM ADT

(106) Safety and Effectiveness of Insulin Aspart versus Other Bolus Insulins in Women with Pre-existing Type 1 Diabetes During Pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(107) The AMerican PREGNANcy-Mother-Child Cohort (AM-PREGNANT): Description and prevalence of main perinatal outcomes and medication use

Favorite

8:00 AM – 1:30 PM ADT

(108) ADHD and induced abortion in young women: a population-based study from Norway

Favorite

8:00 AM – 1:30 PM ADT

(109) Comparing prevalence of neural tube defects and orofacial clefts in Global Burden of Disease study and EUROCAT registry data

Favorite

8:00 AM – 1:30 PM ADT

(110) Determinants of Participation in Clinical Trials During Pregnancy and Lactation

Favorite

8:00 AM – 1:30 PM ADT

(111) Patterns of Antibiotic Utilization for Urinary Tract Infection During Pregnancy, 2007-2020

Favorite

8:00 AM – 1:30 PM ADT

(112) Gabapentin use during pregnancy and adverse neonatal birth outcomes: a population-based cohort study

Favorite

8:00 AM – 1:30 PM ADT

(113) Review of Mother-Infant Linkage Algorithms in Health Care Databases

Favorite

8:00 AM – 1:30 PM ADT

(114) A Comparison of Postpartum Opioid Consumption and Opioid Discharge Prescriptions Among Opioid Naïve Patients and Those With Opioid Use Disorder

Favorite

8:00 AM – 1:30 PM ADT

(115) Associations between Antibiotics and Non-Cardiac Birth Defects, National Birth Defects Prevention Study and Birth Defects Study to Evaluate Pregnancy Exposures

Favorite

8:00 AM – 1:30 PM ADT

(116) Antibiotic exposure during pregnancy: prevalence and associated factors in a French population-based study (2010-2019)

Favorite

8:00 AM – 1:30 PM ADT

(117) Time Trends of HIV Treatment in Girls and Women of Childbearing Age in Germany

Favorite

8:00 AM – 1:30 PM ADT

(118) School readiness among children exposed to opioids during pregnancy in Manitoba, Canada

Favorite

8:00 AM – 1:30 PM ADT

(119) Factors Associated with Health Plan Disenrollment During Pregnancy Among US Commercially Insured Women

Favorite

8:00 AM – 1:30 PM ADT

(120) Maternal acetaminophen intake in pregnancy and the risk of childhood cancer

Favorite

8:00 AM – 1:30 PM ADT

(121) Pregnancy and Fetal Outcomes Following Paternal Exposure to Glatiramer Acetate

Favorite

8:00 AM – 1:30 PM ADT

(122) Antidepressant Use During Trimester One And Pregnancy Loss: A Causal Analysis In The UK CPRD

Favorite

8:00 AM – 1:30 PM ADT

(123) Pregnancy and Fetal Outcomes Following Maternal Exposure to Glatiramer Acetate in 3 Trimesters of Pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(124) Use of multiple sclerosis disease-modifying therapies during pregnancy in France from 2010 to 2021

Favorite

8:00 AM – 1:30 PM ADT

(125) Pregnancy Rates in Patients with Immune-mediated Inflammatory Diseases

Favorite

8:00 AM – 1:30 PM ADT

(126) Long-Term Outcomes of Children exposed to RAAS-Inhibitors During Pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(127) Antidepressant and Psychotherapy Initiation Among Patients with New Episodes of Depression During Pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(128) Clinical Quality of Information of Primary Pregnancy Pharmacovigilance Data Sources – A ConcePTION Project

Favorite

8:00 AM – 1:30 PM ADT

(129) Benefit-Risk Assessment Conceptual Framework for Exposure to Biologics during Pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(130) Lactation Studies of Biologics and Design Challenges

Favorite

8:00 AM – 1:30 PM ADT

(131) Database profile: EPI-MERES, a nationwide mother-child register built from the French National Health Data System (SNDS) for pregnancy and paediatric pharmacoepidemiological research

Favorite

8:00 AM – 1:30 PM ADT

(132) Using a causal framework and electronic health record data to infer the effects of antidepressant exposure in pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(133) Assessment of maternal acetaminophen use during pregnancy: a comparison of self-reported intake with maternal and newborn biomarker measures

Favorite

8:00 AM – 1:30 PM ADT

(134) Core Evidence Elements for generating medicine safety evidence for pregnancy using population-based data: Recommendations from IMI-ConcePTION

Favorite

8:00 AM – 1:30 PM ADT

(135) Congenital Heart Defects Among Infants Linked To Mothers In The Healthcore Integrated Research Database

Favorite

8:00 AM – 1:30 PM ADT

(136) Specifying and mapping design choices from the protocol to the study script in a complex multi-database study to improve transparency and efficiency: the experience of a demonstration project in IMI-ConcePTION

Favorite

8:00 AM – 1:30 PM ADT

(137) The Impact of Psychiatric Diseases and Antiepileptic Drugs Use in Pregnant Women with Epilepsy in Asia Population

Favorite

8:00 AM – 1:30 PM ADT

(138) Monitoring pregnancies exposed to galcanezumab for migraine in a United States (US) administrative claims database

Favorite

8:00 AM – 1:30 PM ADT

(139) Challenges and opportunities of European population-based data sources to support regulatory safety-related research questions in pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(140) Disruptions In Prenatal Care Visits During The Pandemic: A Population-Based Cohort Study in Manitoba, Canada

Favorite

8:00 AM – 1:30 PM ADT

(141) Paxlovid Prophylaxis or Treatment in Pregnancy: Data from the Organization of Teratology Information Specialists (OTIS) Pregnancy Registry

Favorite

8:00 AM – 1:30 PM ADT

(142) Health Literacy and Medication Adherence in Hypertensive Pregnant and Postpartum Patients: A Cross-sectional study

Favorite

8:00 AM – 1:30 PM ADT

(143) A first step to study the use and safety of multiple sclerosis (MS) drugs during pregnancy: identifying cases of MS and assessing MS prevalence. A pilot study in a French health care datasource. A contribution from the ConcePTION project

Favorite

8:00 AM – 1:30 PM ADT

(144) Antiseizure medication safety in pregnant people for non-epilepsy conditions

Favorite

8:00 AM – 1:30 PM ADT

(145) Ponesimod Pregnancy Outcomes Enhanced Monitoring (POEM) Program to Evaluate Reproductive and Embryofetal Toxicity

Favorite

8:00 AM – 1:30 PM ADT

(146) Prevalence of multiple sclerosis in women of childbearing age potential in Europe: A contribution from IMI ConCEPTION

Favorite

8:00 AM – 1:30 PM ADT

(147) Association between non-steroid anti-inflammatory drugs use during pregnancy and premature birth in the NISAMI cohort

Favorite

8:00 AM – 1:30 PM ADT

(148) Assesing the Safety of Antihypertensive medication in Pregnancy (ASAP project)

Favorite

8:00 AM – 1:30 PM ADT

(149) First trimester exposure to smoking cessation pharmacotherapies and the risk of major congenital malformations: A multi-national cohort study

Favorite

8:00 AM – 1:30 PM ADT

(150) Risk of Major Congenital Malformations Associated with Topical Retinoid Use in Pregnancy – Results From Nordic Population-Based Cohorts

Favorite

8:00 AM – 1:30 PM ADT

(151) A Safety Comparison of Continuing Versus Discontinuing Triptans for Acute Migraine Treatment in Early Pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(152) To whom results apply? Assessing the impact of extended continuous enrollment inclusion criteria in pharmacoepidemiologic studies of medication use in pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(153) Patterns Of Antidepressant Prescribing During Pregnancy Between 1996 And 2018 Using The Clinical Practice Research Datalink

Favorite

8:00 AM – 1:30 PM ADT

(154) Maternal mental health during the COVID-19 pandemic and its impact on child cognitive development

Favorite

8:00 AM – 1:30 PM ADT

(155) Maternal Use of Benzodiazepines and Risk of Spontaneous Abortion: A Nationwide Case-Time Control Study

Favorite

8:00 AM – 1:30 PM ADT

(156) The Impact of Nicotine Replacement Therapy on Maternal-Neonatal Outcomes and Smoking Cessation in Pregnant Women: A Systematic Review and Meta-Analysis

Favorite

8:00 AM – 1:30 PM ADT

(157) Childhood cerebral adrenoleukodystrophy (CCALD) in France: epidemiology, natural history, and burden – a real-world study using registry data linked to the French national claims database

Favorite

8:00 AM – 1:30 PM ADT

(158) Healthcare Resource Utilization from OPERA: A Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria

Favorite

8:00 AM – 1:30 PM ADT

(159) Prevalence and use of medications for autoimmune diseases during pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(160) Metabolic Decompensation Events in the Propionic Acidemia Population within a Large EHR-Based Real-World Data Source

Favorite

8:00 AM – 1:30 PM ADT

(161) Impact of population opt-outs on rare disease prevalence: a simulation study

Favorite

8:00 AM – 1:30 PM ADT

(162) Rare disease observational research enabled through the federated data network approach: PHederation use case

Favorite

8:00 AM – 1:30 PM ADT

(163) A Novel Patient-Centered Real-World Evidence Study Designed to Better Understand Short Bowel Syndrome Using Longitudinal Data in the United States

Favorite

8:00 AM – 1:30 PM ADT

(164) Methodological Approaches for External Control Arms in Rare Diseases

Favorite

8:00 AM – 1:30 PM ADT

(165) Improving Longitudinally in Rare Disease Data Capture in Real-world Evidence Combining Clinical Trials and Observational Data: A Case Study Using EVOLVE

Favorite

8:00 AM – 1:30 PM ADT

(166) Novel methods for the identification of a rare disease, hemophagocytic lymphohistiocytosis (HLH)

Favorite

8:00 AM – 1:30 PM ADT

(167) Drug use in presence of contraindications in MG patients in three Italian Regions: a real-world observational study in Italy - The CAESAR study

Favorite

8:00 AM – 1:30 PM ADT

(168) Emicizumab wastage estimation for treating people with hemophilia A and inhibitors who failed immune tolerance induction according to the current Brazilian public health protocol

Favorite

8:00 AM – 1:30 PM ADT

(170) Prevalence and Incidence of Multiple System Atrophy in Real World Setting: Results from US Claims Database

Favorite

8:00 AM – 1:30 PM ADT

(171) Clinical Outcomes and Population Characteristics in Fibrodysplasia Ossificans Progressiva: A Systematic Literature Review

Favorite

8:00 AM – 1:30 PM ADT

(172) A Feasibility Evaluation of US Healthcare Claims Data to Describe Patient Healthcare Utilization Patterns for Dengue Infection

Favorite

8:00 AM – 1:30 PM ADT

(173) Descriptive Epidemiology of Adult T-cell Leukemia/Lymphoma in the United States

Favorite

8:00 AM – 1:30 PM ADT

(174) An expanded algorithm to estimate prevalence of amyotrophic lateral sclerosis in US claims and UK primary care

Favorite

8:00 AM – 1:30 PM ADT

(175) Hereditary angioedema case validation using medical claims data from commercially insured patients

Favorite

8:00 AM – 1:30 PM ADT

(176) Epidemiology and Acute Care Utilization of Patients with Sickle Cell Disease who Present to the Emergency Department

Favorite

8:00 AM – 1:30 PM ADT

(177) Clinical Characteristics of the Propionic Acidemia Population Identified Within a Large EHR-Based Real-World Data Source (2015-2022)

Favorite

8:00 AM – 1:30 PM ADT

(178) Real world evidence in Rare Disease – Application of fit for purpose data sources framework in portopulmonary hypertension

Favorite

8:00 AM – 1:30 PM ADT

(179) Characterizing Patient Care Before And After A Myasthenia Gravis Diagnosis

Favorite

8:00 AM – 1:30 PM ADT

(181) Descriptive Epidemiology of Peripheral T-Cell Lymphoma in the United States

Favorite

8:00 AM – 1:30 PM ADT

(182) Alternative Analytic Approaches to Forming a Benchmark Cohort in Rare Diseases

Favorite

8:00 AM – 1:30 PM ADT

(183) To Estimate the Frequency of Brain Metastases, Presentation of Metastases, Location, Treatment Pattern and paradigm changes in the Brain Metastases Management Among the Population of Southern Asia

Favorite

8:00 AM – 1:30 PM ADT

(184) Challenges and Mitigations of Conducting a Long-Term Effectiveness Study in a Rare Disease (Spinal Muscular Atrophy)

Favorite

8:00 AM – 1:30 PM ADT

(185) Descriptive Characteristics and Validation of Fibrotic Interstitial Lung Disease Patients (ILD) with and without progression Using a Claims Based Algorithm

Favorite

8:00 AM – 1:30 PM ADT

(186) Appropriate Use of Observed Versus Expected Analyses for Newly Emerging Safety Concerns: The Case of Vaccine-Induced Thrombotic Thrombocytopenia Following COVID-19 Vaccination

Favorite

8:00 AM – 1:30 PM ADT

(187) Prevalence of rare blood cancers in Europe: a population-based network cohort study part of DARWIN EU®

Favorite

8:00 AM – 1:30 PM ADT

(188) Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: a cross-sectional study in the United States

Favorite

8:00 AM – 1:30 PM ADT

(189) Development and validation of a claims-based definitional algorithm for moderate asthma exacerbations

Favorite

8:00 AM – 1:30 PM ADT

(190) Medicare Will Negotiate the Prices of Ten Prescription Drugs in 2026: Characteristics of Medicare Beneficiaries Using These Drugs

Favorite

8:00 AM – 1:30 PM ADT

(191) Respiratory Syncytial Virus (RSV) and Bronchiolitis Epidemiology Among the United States Infant Medicaid Populations in Seven States

Favorite

8:00 AM – 1:30 PM ADT

(192) The Burden of RSV and Bronchiolitis in the US Infant Medicaid Population Extends Beyond the Inpatient Setting

Favorite

8:00 AM – 1:30 PM ADT

(193) Healthcare Burden Associated with Atrial Flutter: Analysis of a Nationally Representative, Commercial Claims Database in the United States

Favorite

8:00 AM – 1:30 PM ADT

(194) Incidence of Autoimmune Diseases among Patients with Asthma in the US

Favorite

8:00 AM – 1:30 PM ADT

(195) The TAK-medoids, an algorithm to visualize healthcare pathway pattern on a very large cohort of patients: application on 50 000 French patients with COPD

Favorite

8:00 AM – 1:30 PM ADT

(196) Epidemiology of Injuries among National Basketball Association Players: 2013-14 through 2018-19

Favorite

8:00 AM – 1:30 PM ADT

(197) Using Real-World Data to Evaluate Comparative Effectiveness Cohorts of Azithromycin Relative to Roflumilast in Individuals with Uncontrolled Chronic Obstructive Pulmonary Disease

Favorite

8:00 AM – 1:30 PM ADT

(198) Qualitative Assessment on Access to Treatment and Perceived Challenges Among Asthma Patients in a Hill Village of Nepal

Favorite

8:00 AM – 1:30 PM ADT

(200) Describing clinical outcomes in adults hospitalized with viral lung infections using US real-world data

Favorite

8:00 AM – 1:30 PM ADT

(201) Real-World Data of Lung Cancer: What About Safety?

Favorite

8:00 AM – 1:30 PM ADT

(202) BNT162b2 effectiveness after extending the primary-series dosing interval in children and adolescents

Favorite

8:00 AM – 1:30 PM ADT

(203) Incidence of intussusception among children under 6 years of age in Ningbo, China, 2015-2021: a retrospective cohort study using electronic health records

Favorite

8:00 AM – 1:30 PM ADT

(204) Predicting Drug Consumption in Relation to Respiratory Diseases: An Analysis of the National Organisation for the Provision of Health Services ( EOPYY) Dataset in Greece

Favorite

8:00 AM – 1:30 PM ADT

(205) Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: A systematic review and network meta-analysis of randomized controlled trials

Favorite

8:00 AM – 1:30 PM ADT

(206) Prevalence of Polypharmacy and Hyperpolypharmacy in Patients with Intellectual Disabilities: A Meta-Analysis

Favorite

8:00 AM – 1:30 PM ADT

(207) Value of Serum Procalcitonin in Guiding Anti-infective Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Meta-analysis and Systematic Review

Favorite

8:00 AM – 1:30 PM ADT

(208) Misclassification of Metformin and Insulin Exposure Among Individuals with Type 2 Diabetes Using Integrated Electronic Health Record and Pharmacy Claims Data

Favorite

8:00 AM – 1:30 PM ADT

(209) Optimization-based Stable Balancing Weights vs. Propensity Score Weighting for Samples with High Covariate Imbalance

Favorite

8:00 AM – 1:30 PM ADT

(210) Validation of alopecia coding in US claims data among women of childbearing age

Favorite

8:00 AM – 1:30 PM ADT

(211) Machine Learning Based Prediction of Serious Adverse Events in Metastatic Breast Cancer Patients Receiving Zoledronic Acid

Favorite

8:00 AM – 1:30 PM ADT

(212) Personalized Prescribing Portraits and Evidence Summaries on First-line Antihypertensive Prescribing: A Factorial Randomized Trial of Audit-and-Feedback

Favorite

8:00 AM – 1:30 PM ADT

(213) Variable Selection for Transporting Estimates to Specific Target Populations

Favorite

8:00 AM – 1:30 PM ADT

(214) Validation of Indication for Use (INDO) in the Danish National Prescription Registry

Favorite

8:00 AM – 1:30 PM ADT

(215) Anticholinergic medication used and the risk of delirium in people with dementia- A self-controlled case series study

Favorite

8:00 AM – 1:30 PM ADT

(216) Comparative safety of baricitinib versus TNFi in Rheumatoid Arthritis management in the French population: a propensity score-matched cohort study

Favorite

8:00 AM – 1:30 PM ADT

(217) Risk Assessment of Hypocalcaemia in Patients with Renal Impairment Prescribed Bisphosphonate Preparations Using the MID-NET® in Japan

Favorite

8:00 AM – 1:30 PM ADT

(218) Validity of an ICD-10 Algorithm for Nonfatal Myocardial Infarction Among US Medicare Older Adults

Favorite

8:00 AM – 1:30 PM ADT

(219) Cardiovascular Risk Among Benign Prostatic Hyperplasia Patients Receiving Alpha Blockers and 5-Alpha Reductase Inhibitors

Favorite

8:00 AM – 1:30 PM ADT

(220) Compliance of oral isotretinoin use with prescription and delivery guidelines between 2014 and 2021 in France

Favorite

8:00 AM – 1:30 PM ADT

(222) Defining Provider Prescribing Preference as an Instrumental Variable: A Case Study of NOACs in Stroke Prevention

Favorite

8:00 AM – 1:30 PM ADT

(223) A simulation-based approach to assess the potential impact of unmeasured confounding on study validity at the design stage of non-interventional studies

Favorite

8:00 AM – 1:30 PM ADT

(224) Validity of ICD-10 Algorithms for Ischemic and Hemorrhagic Stroke in US Medicare Older Adults

Favorite

8:00 AM – 1:30 PM ADT

(225) A statistical test for differential sensitivity of study outcome

Favorite

8:00 AM – 1:30 PM ADT

(226) Risk of Type 2 Diabetes Mellitus and Hyperlipidemia in Patients With Chronic Myeloid Leukemia Initiating Tyrosine Kinase Inhibitors: A Nationwide Cohort Study

Favorite

8:00 AM – 1:30 PM ADT

(227) Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis

Favorite

8:00 AM – 1:30 PM ADT

(228) Validity of a Claims-Based Algorithm to Identify Lactic Acidosis in US Medicare

Favorite

8:00 AM – 1:30 PM ADT

(229) Validity of Claims-Based Algorithm to Identify Venous Thromboembolism in Japan

Favorite

8:00 AM – 1:30 PM ADT

(230) Methodological approach for estimating the prevalence of rare cancers in DARWIN EU®

Favorite

8:00 AM – 1:30 PM ADT

(231) Evidence Supporting Product Withdrawals for Safety Reasons in Europe: Shift of the Trend Over Time

Favorite

8:00 AM – 1:30 PM ADT

(232) Understanding Data Source Characteristics Triggering Heterogeneity When Pooling RWD Sources in Pharmacoepidemiological Studies

Favorite

8:00 AM – 1:30 PM ADT

(233) Real-World Incidence of Selected Clinical Events in Patients Diagnosed with Myelofibrosis

Favorite

8:00 AM – 1:30 PM ADT

(234) An iterative phenotype development and evaluation process with medical specialist input: the experience defining progressive multifocal leukoencephalopathy

Favorite

8:00 AM – 1:30 PM ADT

(235) Statin use and sensorineural hearing loss in patients with type 2 diabetes: Evidence from a population-based case-control study

Favorite

8:00 AM – 1:30 PM ADT

(236) Risk factors associated with the incidence of Tyrosine kinase inhibitors-induced cardiac toxicity in cancer patients: a population-based case-control study

Favorite

8:00 AM – 1:30 PM ADT

(237) Polypharmacy and Hyperpolypharmacy among Patients with Chronic Kidney Disease: Prevalence, Geographical Difference, and Associated Factors

Favorite

8:00 AM – 1:30 PM ADT

(238) Real-world Effectiveness and Safety of Multiple Myeloma Treatments Based on Thalidomide and Bortezomib: a Retrospective Cohort Study from 2009 to 2020 in a Brazilian Metropolis

Favorite

8:00 AM – 1:30 PM ADT

(239) Effect of Statin Use for the Primary Prevention of Cardiovascular Disease Among Older Adults: An Observational Analysis Emulating a Target Trial

Favorite

8:00 AM – 1:30 PM ADT

(240) Bridging clinical trial life expectancy (LE) inclusion criterion in the real-world (RW) setting: targeted literature review results for modeling feasibility in relapsed and refractory multiple myeloma (RRMM) patients

Favorite

8:00 AM – 1:30 PM ADT

(241) Assessment of Chemotherapy-Induced Nausea and Vomiting strategies in a resource-constraint setting

Favorite

8:00 AM – 1:30 PM ADT

(242) Using Real World Data to Inform Clinical Trial Design

Favorite

8:00 AM – 1:30 PM ADT

(243) Prescription trends of PCSK9 inhibitors in Hong Kong

Favorite

8:00 AM – 1:30 PM ADT

(244) A comparative safety study of generic alendronate tablet using claims database

Favorite

8:00 AM – 1:30 PM ADT

(245) Percutaneous Transluminal Septal Myocardial Ablation and Common Procedural Complications before and after the approval of Ablysinol

Favorite

8:00 AM – 1:30 PM ADT

(246) Development and Validation of Algorithms to Identify Endometrial Carcinoma Using ICD-9 and ICD-10 Codes in a US Healthcare Claims Database

Favorite

8:00 AM – 1:30 PM ADT

(247) Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D)

Favorite

8:00 AM – 1:30 PM ADT

(248) Application of Machine Learning methods for Prediction of Tyrosine kinase inhibitor-induced hepatotoxicity in Cancer Patients

Favorite

8:00 AM – 1:30 PM ADT

(249) Validation of Diagnoses of Hepatic Disorders in Users of Systemic Antifungal Medication in Sweden

Favorite

8:00 AM – 1:30 PM ADT

(250) The risk of psychiatric hospitalization with medical cannabis: self-controlled case series study

Favorite

8:00 AM – 1:30 PM ADT

(251) Assessment of fluoroquinolone related QT-interval prolonging drug interactions encountered when treating uncomplicated urinary tract infections in women residing in long-term care

Favorite

8:00 AM – 1:30 PM ADT

(252) Effect of Drug-Drug Interaction Between Tamoxifen and CYP2D6-inhibiting Antidepressants on Cancer Recurrence and Mortality of Women with Breast Cancer: a Systematic Review

Favorite

8:00 AM – 1:30 PM ADT

(254) Opioid overdose risk after oxycodone initiation during CYP3A4-inhibiting vs non-inhibiting calcium channel blocker therapy

Favorite

8:00 AM – 1:30 PM ADT

(255) Risk of Severe Uterine Bleeding of Oral Anticoagulants use in Postmenopausal Women Aged 55 Years or Older: An Application of the U.S. Sentinel Routine Querying Tools to the Taiwan Sentinel Data Model

Favorite

8:00 AM – 1:30 PM ADT

(256) Lithium Toxicity Following Co-prescription of Lithium and Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin II Receptor Blockers (ARBs)

Favorite

8:00 AM – 1:30 PM ADT

(257) The risk of fatal opioid overdose associated with the concurrent use of opioid analgesics and psychotropic medicines: a retrospective population-based cohort study

Favorite

8:00 AM – 1:30 PM ADT

(258) The Association between Recently Elevated Anticholinergic Burden and the Risk of Delirium: a case-cross-over study

Favorite

8:00 AM – 1:30 PM ADT

(259) Effectiveness of the influenza vaccine among Korean adult populations from 2015/16 to 2018/19: A Nationwide Population-based Cohort Study

Favorite

8:00 AM – 1:30 PM ADT

(260) Preliminary Findings from a Non-Interventional Post-Authorization Safety Study (PASS) for Active Safety Surveillance of Comirnaty Vaccine Recipients in the EU

Favorite

8:00 AM – 1:30 PM ADT

(261) Low Antibody Titers Demonstrate Significantly Increased Risk of SARS-CoV-2 Infection in a Highly Vaccinated Population from the National Basketball Association

Favorite

8:00 AM – 1:30 PM ADT

(262) Signal detection, refinement, & evaluation of cerebral venous sinus thrombosis following Spikevax administration in a US active surveillance system

Favorite

8:00 AM – 1:30 PM ADT

(263) Post-Authorization Safety Study: Cohort Event Monitoring for CYD-TDV Dengue Vaccine (DNG15)

Favorite

8:00 AM – 1:30 PM ADT

(264) Are maternal vaccines effective and safe in mothers and infants? A systematic review and meta-analysis of randomized controlled trials

Favorite

8:00 AM – 1:30 PM ADT

(266) Changes in vaccination patterns for infants after the introduction of DTaP-IPV/Hib combination vaccines

Favorite

8:00 AM – 1:30 PM ADT

(267) Endemic Human Coronaviruses: An Opportunity for Vaccination

Favorite

8:00 AM – 1:30 PM ADT

(268) Exploring determinants of vaccine hesitancy among pregnant women: a behavioral analysis using Theoretical Domains Framework

Favorite

8:00 AM – 1:30 PM ADT

(269) Association between simultaneous vaccination with live and inactivated vaccines and risk of hospitalization for non-vaccine-targeted infections

Favorite

8:00 AM – 1:30 PM ADT

(270) Association between Enterovirus 71 (EV71) Vaccination and Risk of Henoch‑Schönlein purpura: a Population-based Near Real-Time Surveillance Study

Favorite

8:00 AM – 1:30 PM ADT

(271) Utilization of a Hybrid Data Environment Linking Registry, Claims and EHR to Identify Myocarditis Patients

Favorite

8:00 AM – 1:30 PM ADT

(272) Estimation of association between Vaccine Associated Paralytic Poliomyelitis and Polio Vaccine using VAERS Database: A 34 Year Data Mining

Favorite

8:00 AM – 1:30 PM ADT

(273) Validation of a Claims-based Algorithm for Myocarditis/Pericarditis in Pediatric Patients

Favorite

8:00 AM – 1:30 PM ADT

(274) The immunogenicity and Safety of the BBIBP-CorV (Sinopharm) Inactivated SARS-COV-2 Vaccine: A Prospective Observational Study in Indonesia

Favorite

8:00 AM – 1:30 PM ADT

(275) Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine in China: a retrospective real-world study

Favorite

8:00 AM – 1:30 PM ADT

(276) Healthcare Utilization Trends for RSV, Influenza, and Pneumonia among Children and Older Adults in 2020-2022

Favorite

8:00 AM – 1:30 PM ADT

(277) RSV Outcomes Study Extension (ROSE): Epidemiological and Operational Considerations for an Observational Study Linking Real-World Data through Tokenization to the mRNA-1345 RSV Vaccine Phase 3 Clinical Trial Data in Adults

Favorite

8:00 AM – 1:30 PM ADT

(278) Adapting clinical endpoints to a real-world setting in vaccine effectiveness and safety studies

Favorite

8:00 AM – 1:30 PM ADT

(279) Response rate of participant centered active surveillance of adverse event following immunization: A systematic review and Meta-analysis

Favorite

8:00 AM – 1:30 PM ADT

(281) Human Papilloma Virus vaccine: India has Knowledge & Intention-action gap?

Favorite

8:00 AM – 1:30 PM ADT

(282) Representation of study scripts to improve transparency and efficiency in multidatabase distributed vaccine studies

Favorite

8:00 AM – 1:30 PM ADT

(283) The Impact of Guideline and Formulary Changes on Prescribing of Oral Vancomycin and Fidaxomicin for Treatment of Clostridioides Difficile Infections in Ontario Canada

Favorite

8:00 AM – 1:30 PM ADT

(284) Rural Residence is Associated with Limited Guideline Concordant Cholesterol Management in Newly Treated Type 2 Diabetes

Favorite

8:00 AM – 1:30 PM ADT

(285) Auditing Antibiotic Dispensing Practices in Community Pharmacies in 5 EU Countries

Favorite

8:00 AM – 1:30 PM ADT

(286) Explaining Regional Variations in Outpatient Antibiotic Prescribing: A Small Area Analysis Including Over 16 Million Persons in Germany

Favorite

8:00 AM – 1:30 PM ADT

(287) A Cross-Sectional Evaluation of Anticoagulation Control in Patients Receiving Warfarin in Nine African Countries

Favorite

8:00 AM – 1:30 PM ADT

(288) Do’s and Don’ts for the European Community Pharmacist When Dispensing Antibiotics: A Delphi Study

Favorite

8:00 AM – 1:30 PM ADT

(289) Survival benefit of direct-acting antiviral agents on HCV-related HCC

Favorite

8:00 AM – 1:30 PM ADT

(290) Helicobacter Pylori Eradication Treatment and Subsequent Colorectal Cancer (CRC) Risk

Favorite

8:00 AM – 1:30 PM ADT

(291) The Real-Life Effectiveness of Antiviral Therapy in Hepatocellular Carcinoma Patients with Low HBV-DNA Levels After Hepatectomy: A Retrospective Cohort Study in Taiwan

Favorite

8:00 AM – 1:30 PM ADT

(292) Infection and Risk of Breast Cancer Recurrence: A Danish Nationwide Case-Control Study

Favorite

8:00 AM – 1:30 PM ADT

(293) Association Between β-lactam Allergy Documentation and Outpatient Antibiotic Prescribing in Primary Healthcare Facilities in China

Favorite

8:00 AM – 1:30 PM ADT

(294) Drug use evaluation comparing sedative-hypnotic drug use in hospitalized inpatients in two Canadian community hospitals

Favorite

8:00 AM – 1:30 PM ADT

(296) A Post Authorization Safety Study of Long-Term Voriconazole Use in Sweden: A Population Based Cohort Study

Favorite

8:00 AM – 1:30 PM ADT

(297) Frequency of adverse events of antiretroviral therapy in women living with HIV/AIDS: a systematic review and meta-analysis

Favorite

8:00 AM – 1:30 PM ADT

(298) Effectiveness of Monovalent COVID-19 Booster/Additional Vaccine Doses in the United States

Favorite

8:00 AM – 1:30 PM ADT

(299) Effectiveness of a Fourth Dose of mRNA-1273 Vaccine Against COVID-19 Among Older Adults in the United States

Favorite

8:00 AM – 1:30 PM ADT

(300) Effectiveness of mRNA-1273 Bivalent (original and omicron BA.4/BA.5) COVID-19 Vaccine Against Hospitalizations for COVID-19, Medically Attended SARS-CoV-2 Infections, and COVID-19 Hospital Deaths in the United States

Favorite

8:00 AM – 1:30 PM ADT

(301) Methodological development of an enhanced safety surveillance for the Janssen COVID-19 vaccine (JCOVDEN) through rapid cycle analysis of US administrative claims data

Favorite

8:00 AM – 1:30 PM ADT

(302) Changing Profiles of Populations Receiving COVID-19 Vaccines - Differing Underlying Risks for Adverse Events

Favorite

8:00 AM – 1:30 PM ADT

(303) Cardiovascular, neurological, and immunological adverse events associated with 23-valent pneumococcal polysaccharide vaccine among older adults: a nationwide self-controlled risk interval study

Favorite

8:00 AM – 1:30 PM ADT

(304) Effectiveness of COVID-19 Vaccine in SARs-CoV-2 Infected Patients with Chronic Kidney Disease

Favorite

8:00 AM – 1:30 PM ADT

(305) Risk of gestational outcomes and adverse events following immunization with influenza vaccine in pregnant women

Favorite

8:00 AM – 1:30 PM ADT

(C01) Agreement of COVID-19 Incidence Between the Authoritative Data and Real-World Evidence in England

Favorite

8:00 AM – 1:30 PM ADT

(C02) Anonymized tokenization technology to link real world data and assess the potential for exposure misclassification for pharmacoepidemiology research

Favorite

8:00 AM – 1:30 PM ADT

(C03) Contemporary pharmacoepidemiology practice for real world data source identification and feasibility assessment – Results from an ISPE-sponsored online survey

Favorite

8:00 AM – 1:30 PM ADT

(C04) European Rare Disease Registries: A Collaborative Effort to Assess the Quality and Suitability of Registries to Describe the Natural History of Disease and Treatment Landscape of Spinal Muscular Atrophy

Favorite

8:00 AM – 1:30 PM ADT

(C05) Phased Target Trial Design and Meta-Analysis in a Head-to-Head Treatment Comparison

Favorite

8:00 AM – 1:30 PM ADT

(C06) The risk of incident dementia and Alzheimer’s disease after the use of centrally-acting versus non-centrally acting angiotensin-converting enzyme inhibitors: a target trial emulation study

Favorite

8:00 AM – 1:30 PM ADT

(C08) Using Historical RCT Controls to Contextualize Necessity of Unblinding of Serious Adverse Events and Adverse Events of Special Interest – Conceptual Framework and Database Development

Favorite

8:00 AM – 1:30 PM ADT

(C09) Diabetes medication use in digital hospitals in China: a cross-sectional descriptive study

Favorite

8:00 AM – 1:30 PM ADT

(C10) Early identification of patients at risk for Type-2 diabetes using machine learning models

Favorite

8:00 AM – 1:30 PM ADT

(C11) Effect of Mobile Applications on the Spontaneous Reporting of Adverse Drug Reactions: A Systematic Review and Individual Patient Data Meta-Analysis

Favorite

8:00 AM – 1:30 PM ADT

(C12) Identification of Treatment-Resistant Major Depressive Disorder using a Machine Learning Algorithm

Favorite

8:00 AM – 1:30 PM ADT

(C13) Machine learning (ML) model for prediction of pneumonitis using real-world data (RWD) on immune checkpoint inhibitor (ICI)-treated advanced non-small cell lung cancer (aNSCLC)

Favorite

8:00 AM – 1:30 PM ADT

(C14) Switching codeine to a prescription-only drug successfully reduced public engagement: An exploratory analysis using Google Trends

Favorite

8:00 AM – 1:30 PM ADT

(C15) Use of A Wearable Activity Tracker to Assess Differences in REM Sleep Duration Among Adolescents With and Without Depression

Favorite

8:00 AM – 1:30 PM ADT

(C16) Wearables and digital tools for infectious disease: Overview of existing digital contact tracing systems

Favorite

8:00 AM – 1:30 PM ADT

(C17) Do Enrollment Gaps Matter? A Real-World Study of Administrative Health Claims Gaps Using the Sentinel Common Data Model

Favorite

8:00 AM – 1:30 PM ADT

(C18) Drug Utilization Patterns among Patients Hospitalized with COVID-19 in the United States, January 2021– February 2022

Favorite

8:00 AM – 1:30 PM ADT

(C19) Opioid and benzodiazepine prescribing patterns for noncancer pain in primary care practices in Nova Scotia, Canada from 2011-2018

Favorite

8:00 AM – 1:30 PM ADT

(C20) Patient characteristics and treatment patterns for migraine patients initiating erenumab in Denmark and Sweden

Favorite

8:00 AM – 1:30 PM ADT

(C21) Paxlovid or Molnupiravir Post-Treatment Medication Use Evaluation of Rebound COVID-19

Favorite

8:00 AM – 1:30 PM ADT

(C22) Plaque Psoriasis in the Real-World Setting: Disease Activity and Initiation of Advanced Therapy

Favorite

8:00 AM – 1:30 PM ADT

(C23) Racial-Ethnic Differences in ADHD Diagnosis and Pharmacotherapy Among Adolescents and Emerging Adults in a US Commercial Healthcare Claims Database

Favorite

8:00 AM – 1:30 PM ADT

(C24) Temporal Trends in Use of Old and New Intravenous Iron Formulations among US Medicare Beneficiaries, 2008-2019

Favorite

8:00 AM – 1:30 PM ADT

(C25) A data mining approach for the discovery of potentially high- and low-risk high-order drug combinations from real world data

Favorite

8:00 AM – 1:30 PM ADT

(C26) A Review of Existing Clinical Guideline Recommendations for Contraceptive Selection in Women with Epilepsy with a Focus on Drug-Drug Interactions

Favorite

8:00 AM – 1:30 PM ADT

(C27) Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and the risk of major bleeding in patients with atrial fibrillation

Favorite

8:00 AM – 1:30 PM ADT

(C28) Evaluation of QT Prolongation Associated with Haloperidol Using KIDS-KAERS Database, 2016-2020

Favorite

8:00 AM – 1:30 PM ADT

(C29) Network Analysis of Anticholinergic Medication Use in a Cohort of People Aging with HIV: Identification of Anticholinergic Medication Drivers of Physical Frailty States

Favorite

8:00 AM – 1:30 PM ADT

(C30) Review of Case Reports and Analysis of VigiBase Data to Identify Potential Cannabis Natural-Product Drug Interactions

Favorite

8:00 AM – 1:30 PM ADT

(C31) The effect of isoniazid use for tuberculosis prevention on pregnancy incidence among women living with HIV on antiretroviral treatment and progestin-based hormonal contraception

Favorite

8:00 AM – 1:30 PM ADT

(C32) The Interaction Between Gliclazide and Omeprazole via CYP2C19 and the Risk of Hypoglycaemia: A Case-Crossover Study using Primary Care Data from the UK

Favorite

8:00 AM – 1:30 PM ADT

(C33) Effects of PM2.5 Exposure and Anticoagulant Use on Bleeding Events in a High-Risk Medicare Cohort: Evidence of Drug - Air Pollution Interaction

Favorite

8:00 AM – 1:30 PM ADT

(C34) Environmental burden and utilization of analgesics around Lake Mälaren, Sweden’s largest drinking water source

Favorite

8:00 AM – 1:30 PM ADT

(C35) Geographical visualization of urinary Escherichia coli resistance in the Illawarra region, Australia

Favorite

8:00 AM – 1:30 PM ADT

(C36) Human health risk assessment and meta-analysis of arsenic-contaminated drinking water in endemic regions of India

Favorite

8:00 AM – 1:30 PM ADT

(C37) Changes in Comorbidity / Multimorbidity within 5 Years, Post-Recruitment into the UK Biobank

Favorite

8:00 AM – 1:30 PM ADT

(C38) Effects of Genetic Polymorphism and Drug-Drug Interaction on Outcomes of Clopidogrel Treatment

Favorite

8:00 AM – 1:30 PM ADT

(C39) Genetic polymorphism and risk of anti-tuberculosis drug-induced liver injury (ATDILI): a systematic review and meta-analysis

Favorite

8:00 AM – 1:30 PM ADT

(C40) Implementing Mendelian randomization to assess foetal risk from intrauterine prescriptive drugs for the treatment of glycaemic conditions, hypertension and thyroidism in pregnancy

Favorite

8:00 AM – 1:30 PM ADT

(C41) Individual and Interactive Effects of Three Common Polymorphisms in APOA1 Gene and Obesity on Lipid-lowering Efficacy of statin

Favorite

8:00 AM – 1:30 PM ADT

(C42) Pharmacogenetic Testing in Switzerland: a Descriptive Study Using Swiss Claims Data

Favorite

8:00 AM – 1:30 PM ADT

(C43) Sclerostin inhibition and cardiovascular risk: triangulating the evidence using Mendelian randomisation methods

Favorite

8:00 AM – 1:30 PM ADT

(C44) Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Children in Switzerland: a Descriptive Study Using Swiss Claims Data

Favorite

8:00 AM – 1:30 PM ADT

(C45) Comparative safety of adding SNRIs versus NSAIDs to short-acting opioid for non-malignant pain in nursing homes

Favorite

8:00 AM – 1:30 PM ADT

(C46) Evidence-based data for the use of newly approved medications in older adults: a descriptive analysis from clinical trials to product monographs

Favorite

8:00 AM – 1:30 PM ADT

(C47) Heterogeneous Treatment Effects of Metformin on the Risk of Dementia in People with Type 2 Diabetes: A Longitudinal Observational Study

Favorite

8:00 AM – 1:30 PM ADT

(C48) Incidence and prevalence of Parkinson’s disease and utilisation of antiparkinson treatments: a population-based cohort study

Favorite

8:00 AM – 1:30 PM ADT

(C49) Potential inappropriate medication use among older patients with Parkinson’s disease: A cross sectional analysis of a national health insurance database in China

Favorite

8:00 AM – 1:30 PM ADT

(C50) Redefining Polypharmacy in Older People Taking into Account Longitudinality: A Joint Latent Class Analysis

Favorite

8:00 AM – 1:30 PM ADT

(C51) Statins discontinuation near the end of life: a retrospective cohort study using electronic health records

Favorite

8:00 AM – 1:30 PM ADT

(C52) Validating Medicare claims-based algorithms for deprescribing of benzodiazepines using a novel linkage with electronic health records data

Favorite